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ABSTRACT 
Objective: To examine the effects of short-, medium- and long-term resistance 
exercise training (RET) on measures of cardio-metabolic health in adults. 
Design: Intervention systematic review  
Data sources: MEDLINE and Cochrane Library databases were searched from 
inception to February 2018. The search strategy included the keywords: resistance 
exercise, strength training, randomised controlled trial. 
Eligibility criteria for selecting studies: RCTs published in English comparing RET 
>2 weeks in duration with a non-exercising control or usual care group. Participants 
were non-athletic and aged ≥18 years. 
Results: A total of 173 trials were included. Medium- and long-term RET reduced 
systolic blood pressure (-4.02 [95% CI: -5.92, -2.11], mmHg P < 0.0001 and -5.08 [-
10.04, -0.13] mmHg, P = 0.04, respectively) and diastolic blood pressure (-1.73 [-2.88, 
-0.57] mmHg, P = 0.003 and -4.93 [-8.58, -1.28] mmHg, P = 0.008, respectively) versus 
control. Medium-term RET elicited reductions in fasted insulin and insulin resistance 
(-0.59 [-0.97, -0.21] µU/ml, P = 0.002 and -1.22 [-2.29, -0.15] µU/ml, P = 0.02, 
respectively). The effects were greater in those with elevated cardio-metabolic risk or 
disease compared to younger healthy adults. The quality of evidence was low or very 
low for all outcomes. There was limited evidence of adverse events. 
Conclusions: RET may be effective for inducing improvements in cardio-metabolic 
health outcomes in healthy adults and those with an adverse cardio-metabolic risk 
profile.  
 
 
KEYWORDS: cardiovascular, exercise training, systematic review, strength training 
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INTRODUCTION 
Cardiovascular disease is a substantial human and economic burden, responsible for 
17.7 million deaths globally in 2015 [1]. The positive impact of regular moderate to 
vigorous intensity aerobic exercise (e.g. brisk walking, jogging, cycling) on cardio-
metabolic health, including improvements in cardiopulmonary exercise capacity, blood 
pressure, glycaemic control, hypercholesterolemia and vascular endothelial function 
[2, 3], is well-documented and recognised in current UK and global physical activity 
recommendations [4, 5]. However, while the health benefits of regular resistance 
exercise training (RET) in relation to maintaining skeletal muscle size and strength are 
also recognised in current physical activity recommendations, the role of RET in 
enhancing cardio-metabolic health is less well defined.  
RET is characterised by muscular activities working against an external load and may 
be easier than aerobic exercise to implement and sustain in the home environment as 
it offers an alternative way to exercise for older adults who have limited space or 
access to equipment and time availability [6-8]. Most studies of RET have focused on 
changes in skeletal muscle size and strength, with few investigating cardio-metabolic 
health effects as primary outcomes although several have reported cardio-metabolic 
variables as secondary outcomes [9, 6, 10]. 
There is preliminary evidence that RET may positively alter blood lipid profile, body 
composition, systolic blood pressure [11-13], circulating inflammatory markers and 
cardiopulmonary exercise capacity [14, 15, 2]. RET may also generate longer-lasting 
improvements in body fat, fasted insulin, lipid profile and systolic blood pressure than 
aerobic exercise [16, 17]. Finally, RET may have an important role in attenuating age-
related physiological changes such as increases in systolic blood pressure and arterial 
stiffness, and the reduction of skeletal muscle mass (with associated changes in 
systemic physiology) [18, 3]. 
Aside from the lack of RET intervention studies with a primary focus on cardio-
metabolic health outcomes, interpreting the impact of RET on cardio-metabolic health 
is constrained by heterogeneity of methodology, including the duration of interventions 
and populations. High-quality systematic reviews and meta-analyses can help to 
overcome these challenges, while accounting for bias and heterogeneity, by providing 
more precise estimates of effect size changes. The aim of this systematic review was 
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to assess the effects of short-, medium- and long-term RET programmes compared to 
control or usual care on cardio-metabolic health outcomes in adults. 
 
METHODS 
The preferred reporting items for systematic review and meta-analyses (PRISMA) 
guidelines were followed [19] when conducting and reporting this prospectively 
registered systematic review (PROSPERO ID CRD42016037946). 
Eligibility criteria 
We included randomised controlled trials (RCTs) published in English that compared 
any RET programme alone to a non-exercising control or usual care group. 
Participants must have been aged  18 years, non-athletic [20], and recruited to a RET 
programme (e.g. elastic resistance band, weight machines, etc.) of at least 2 weeks 
duration, irrespective of intensity or frequency that was conducted in any setting (e.g. 
home, hospital). We included studies where isometric RET with whole body vibration 
was used. We excluded studies where RET interventions were combined with other 
lifestyle components or exercise modes (e.g. aerobic exercise, diet, etc.) to isolate the 
effects of RET. Studies that included at least one of the following cardio-metabolic 
health outcomes or clinical end-points were eligible: V̇O2max; flow-mediated dilatation; 
C-reactive protein; total cholesterol; high-density lipoprotein cholesterol; low-density 
lipoprotein cholesterol; triglycerides; fasted glucose; fasted insulin; insulin resistance 
(HOMA-IR); resting blood pressure; mean arterial pressure; resting heart rate; 
cardiovascular mortality;  all-cause mortality; non-fatal end-points (e.g. myocardial 
infarction, coronary artery bypass grafting; percutaneous transluminal coronary 
angioplasty; angina or angiographically-defined coronary heart disease; stroke; 
carotid endarterectomy; peripheral arterial disease.  
Search strategy  
The MEDLINE Ovid and Cochrane Library databases were searched from inception 
to February 2018. The search strategy keywords and MeSH terms used included: 
progressive resistance, strength training, exercise and randomised controlled trial. 
Details of the full search strategy can be found in supplementary table 1. Reference 
lists of all relevant systematic reviews identified were searched for additional studies. 
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All searches were conducted by the same author (RA), with search results collated 
using EndNote software (Thomson Reuters, New York), and duplicates removed. 
The first 10% of titles and abstracts were screened independently by two reviewers 
(RA and GT) and, due to good agreement, the remaining texts were screened by one 
reviewer only (RA, GT, JS or LL) [21]. Screening of full-texts was performed by two 
independent reviewers (RA and GT) with disagreements resolved through consensus 
or a third reviewer being consulted (JS).  
Data extraction  
Two authors (RA and SG) independently extracted data using Microsoft Excel. Any 
disagreements were resolved via consensus. When more than one publication was 
apparent for the same trial, data were collated (supplementary table 2). We extracted 
study design, participant demographics, intervention details and means and standard 
deviations for all outcomes. When necessary, published protocols and trial registries 
were searched for further methodological detail and risk of bias assessment. If there 
was insufficient information the authors (n = 40) were contacted via email. Resting 
blood pressure was expressed in millimetres of mercury (mmHg); resting heart rate in 
beats per minute (bpm), V̇O2max relative to body mass (ml/kg/min), flow-mediated 
dilatation as percentage, fasted insulin in micro units per millilitre (µU/ml), C-reactive 
protein in milligrams per litre (mg/L) and glucose, lipid profile and HOMA-IR in 
milligrams per decilitre (mg/dL). Adverse events were also extracted.  
Risk of bias 
Risk of bias was assessed by two authors independently (RA and SG) using the 
Cochrane Risk of Bias tool [22]. Any disagreements were resolved through consensus. 
We judged risk of bias on the study level as ‘low’, ‘unclear’ or ‘high’ risk [23]. We used 
funnel plots to assess publication bias when there were more than 10 studies 
contributing data for an analysis [24, 23]. For all outcomes we conducted sensitivity 
analyses. For the sensitivity analyses, we excluded studies that were judged as being 
at unclear risk of bias on a majority of domains of the Cochrane tool, or where at least 
2 domains of the Cochrane tool were judged as being at high risk of bias, and ran the 
meta-analysis again.  
Data synthesis 
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Meta-analyses were undertaken using Review Manager (RevMan 5.3; Cochrane 
Collaboration, Oxford, UK) when more than two studies reported on the same 
outcome. In the pooled analysis of studies by duration, outcome data were organised 
into short-term (≤6 weeks), medium-term (7-23 weeks) and long-term (≥24 weeks) 
arbitrary categories. Where units of measurement could not be converted, 
standardised mean differences (SMD) were used. Data are presented as mean and 
95% confidence intervals. The I² statistic was used to quantify statistical heterogeneity 
as follows: 0-40%: might not be important, 30-60%: moderate heterogeneity, 50-90%: 
substantial heterogeneity, 75-100%: considerable heterogeneity [23]. Fixed-effects 
model was used for analysis however, if statistical heterogeneity was noted (I2 >40%), 
meta-analysis was performed using a random-effects model. The GRADE approach 
was used to assess the strength of evidence. Studies were downgraded if there were 
issues with risk of bias, consistency, precision or directness of the outcomes. The 
reasons for downgrading the evidence are outlined in Table 1. 
 
Table 1. Criteria for downgrading the quality of outcomes using the GRADE approach. 
 
 
 
 Reason to downgrade the level of evidence 
Risk of bias  Majority of studies rated as being at unclear risk of bias  
 Outcome includes studies that have been rated as being at 
high risk of bias in 2 or more categories 
Inconsistency  Large heterogeneity based on the similarity of point 
estimates, statistical heterogeneity and I2  50% 
Imprecision  Large confidence intervals when data are presented as 
standardised mean difference 
 Substantial heterogeneity (I2  50%) 
 If a recommendation or clinical course of action would differ 
if the upper versus the lower boundary of the confidence 
interval represented the truth 
 Sample size < 400 within the meta-analysis for each 
variable 
Indirectness  Use of surrogate outcomes 
Publication bias  Asymmetric funnel plot 
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Where multiple RET groups were compared to a single control group, data for the 
intervention most similar to traditional RET was used for the analysis. After the initial 
analysis, sub-group analyses were conducted to explore sources of heterogeneity by 
dividing studies into three categories: healthy young adults aged 18-40 years; healthy 
older adults ≥ 41 years old; older adults ≥ 41 years old with elevated cardio-metabolic 
risk or established disease (defined as any elevated blood marker above normal levels 
or overweight, obese or hypertensive participants). Adverse events were synthesised 
descriptively. 
 
RESULTS 
A total of 19,040 records were retrieved from database searches, of which 5,669 
records were duplicates. A further 11,696 were then eliminated following screening of 
titles and abstracts (Figure 1). Sixty-three potentially relevant papers were identified 
from screening of systematic review reference lists (Figure 1). After full-text screening 
of 1,738 articles, 194 manuscripts from 173 RCTs were included in this review (Figure 
1). Participants were individually randomised in all included trials (i.e. there were no 
cluster RCTs). 
 
 
 
 
 
 
 
 
Figure 1. PRISMA flow diagram 
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Study characteristics 
The 173 RCTs comprised 6,169 participants (2,840 control and 3,329 RET 
participants), with sample sizes of 5-77 per group and 13-150 per study. One hundred 
studies involved healthy individuals and 73 studies involved clinical populations. All 
included studies were published between 1978 and February 2018. Summary details 
of the included trials and populations are presented in supplementary table 2 and 3 
respectively.   
RET programmes mainly used weight machines (n = 90 studies; 52%), a mix of free 
weights, bodyweight and machine exercises (n = 43 studies; 25%), elastic resistance 
bands (n = 13 studies; 8%), circuit exercises (n = 12 studies; 7%), free weights (n = 
10 studies; 6%), ankle/leg weights (n = 2 studies; 1%), isometric hand grip (n = 2 
studies; 1%) and isometric exercise with whole body vibration (n = 1 study). 
The majority of interventions were supervised by an exercise professional (n = 105 
studies; 61%). One study reported data from an unsupervised intervention, and 13 
(8%) used a combination of supervised and unsupervised programmes. Fifty-four 
studies (31%) did not report the level of supervision.  
The duration of the intervention varied from ≤ 6 weeks (n = 13), 7-23 weeks (n = 129) 
and ≥ 24 weeks (n = 31). The most common frequency of training was 3 sessions per 
week (n = 110), followed by 2 sessions per week (n = 36), though some studies 
required participants to complete the programme in 1, 4 or 5 sessions per week (n = 
1, n = 7 and n = 5, respectively). The remaining studies stipulated either two-three 
sessions per week (n = 8), three-four sessions per week (n = 1) or did not report the 
frequency (n = 5).  
In the majority of studies, control participants were instructed to continue with their 
habitual activity (n = 115/173) or were allocated to usual care (n = 15). Three studies 
provided lifestyle advice to the control group and discussion about physical activity 
levels, but no structured/supervised exercise (n = 3). Forty studies did not report the 
requirements of the control group. The included studies did not report any clinical end-
points. A summary of the quality of evidence, based on risk of bias, study design, 
confidence intervals and variability in results, has been collated using the GRADE 
approach (Table 2).  
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Table 2. GRADE summary of findings. 
 
Outcome 
Anticipated absolute effects (95% CI) Number of 
participants 
(RCTs) 
Certainty Risk with 
control group Risk with resistance exercise training 
Cardiovascular morbidity/mortality Could not be calculated due to lack of reporting. 
Systolic blood pressure 
(mmHg) 
ST 115.45 mmHg MD 3.17 mmHg lower  (6.95 lower to 0.6 higher) 116 (4 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 122.8 mmHg MD 4.02 mmHg lower  (5.92 lower to 2.11 lower) 1456 (46 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 131.6 mmHg MD 4.88 mmHg lower  (10.55 lower to 0.78 higher) 346 (7 RCTs) ⊕⊕◯◯ LOW a,c 
Mean arterial pressure 
(mmHg) 
ST 86.5 mmHg MD 3.31 mmHg lower (6.86 lower to 0.78 higher) 67 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
MT 79.6 mmHg MD 1.57 mmHg lower (4.6 lower to 1.46 higher) 238 (10 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
Diastolic blood pressure 
(mmHg) 
ST 65.2 mmHg MD 1.44 mmHg lower (4.73 lower to 1.86 higher) 52 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 74.3 mmHg MD 1.73 mmHg lower (2.88 lower to 0.57 lower) 1418 (45 RCTs) ⊕⊕◯◯ LOW a,c 
LT 76 mmHg MD 4.93 mmHg lower (8.58 lower to 1.28 lower) 346 (7 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
Resting heart rate (bpm) ST 72 bpm MD 2.66 bpm lower (7.55 lower to 2.23 higher) 30 (2 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
MT 67.8 bpm  MD 0.35 bpm higher (1.44 lower to 2.13 higher) 977 (35 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 57.4 bpm MD 0.48 bpm lower (3.12 lower to 2.17 higher) 142 (5 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
Flow Mediated Dilatation (%) 7.8 % MD 1.69 % higher (0.97 higher to 2.41 higher) 138 (6 RCTs) ⊕⊕◯◯ LOW a,c 
Total Cholesterol 
(mg/dL)  
 
ST 179.3 mg/dL MD 5.55 mg/dL lower (9.62 lower to 5.47 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,c,e 
MT 180.9 mg/dL MD 0.57 mg/dL higher (5.63 lower to 6.77 higher) 882 (32 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 198.6 mg/dL MD 8.71 mg/dL lower (30.83 lower to 13.4 higher) 212 (8 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d,e 
High-density 
lipoprotein 
cholesterol (mg/dL)  
 
ST 53.8 mg/dL MD 0.82 mg/dL higher (5.4 lower to 7.03 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 53.3 mg/dL MD 2.35 mg/dL higher (0.66 lower to 5.35 higher) 1114 (38 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 53.5 mg/dL MD 2.79 mg/dL higher (0.69 lower to 6.82 higher) 339 (9 RCTs) ⊕⊕◯◯ LOW a,c 
Low-density 
lipoprotein 
cholesterol (mg/dL)  
 
ST 105.6 mg/dL MD 5.1 mg/dL lower (11.09 lower to 0.9 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 110.1 mg/dL MD 2.86 mg/dL lower (8.77 lower to 3.05 higher) 1000 (31 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 118.3 mg/dL MD 3.69 mg/dL lower (10.99 lower to 3.6 higher) 265 (6 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
Triglycerides (mg/dL)  
 
ST 115.2 mg/dL MD 3.63 mg/dL lower (17.45 lower to 10.2 higher) 146 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 91.8 mg/dL MD 3.99 mg/dL lower (8.78 lower to 0.8 higher) 1165 (37 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 102.7 mg/dL MD 2.82 mg/dL lower (14.98 lower to 9.33 higher) 265 (6 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
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Table 2 cont. 
 
Fasted insulin (μU/ml) MT 16.2 μU/ml MD 1.11 μU/ml lower (1.74 lower to 0.49 lower) 590 (20 RCTs) ⊕◯◯◯ VERY LOW a,c,d	
LT 13.8 μU/ml MD 0.4 μU/ml lower (1.62 lower to 0.81 higher) 179 (4 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d	
HOMA-IR  
 
MT 6.1 MD 1.22 lower (2.29 lower to 0.15 lower) 184 (9 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
LT 3.8 MD 0.18 lower (0.64 lower to 0.27 higher) 71 (3 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
Fasted glucose 
(mg/dL)  
 
ST 87.3 mg/dL MD 3.39 mg/dL lower (6.9 lower to 0.11 higher) 122 (2 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 100.7 mg/dL MD 2.39 mg/dL lower (4.47 lower to 0.31 lower) 984 (34 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
LT 92.3 mg/dL MD 0.7 mg/dL lower (2.8 lower to 2.67 higher) 271 (7 RCTs) ⊕◯◯◯ VERY LOW a,b,c,d 
C-reactive protein 
(mg/L)  
 
ST 2.4 mg/L MD 0.13 mg/L lower (0.25 lower to 0.01 lower) 82 (2 RCTs) ⊕◯◯◯ VERY LOW a,b,c,e 
MT 3.2 mg/L MD 0.11 mg/L lower (0.6 lower to 0.38 higher) 394 (12 RCTs) ⊕◯◯◯ VERY LOW a,c,d 
Aerobic capacity (ml/kg/min) ST 28.6 ml/kg/min MD 2.07 ml/kg/min higher (0.75 higher to 3.39 
higher) 
308 (9 RCTs) ⊕◯◯◯ VERY LOW a,b,c 
MT 28.9 ml/kg/min MD 1.07 ml/kg/min higher (0.38 higher to 1.76 
higher) 
1454 (48 RCTs) ⊕◯◯◯ VERY LOW a,c,d,e 
LT 23 ml/kg/min MD 1.22 ml/kg/min higher (0.44 higher to 2.0 
higher) 
399 (11 RCTs) ⊕◯◯◯ VERY LOW a,c,e 
CI - Confidence interval; RCTs – randomised controlled trials; MD – mean difference; ST – short term; MT – medium term; LT – long term 
a – Downgraded due to being a surrogate outcome. 
b – Downgraded due to potential for a recommendation or clinical course of action differing if the upper versus the lower boundary of the CI represented the truth 
and/or a sample size <400. 
c – Publication bias suspected after inspection of funnel plots. 
d – Inconsistent due to high heterogeneity, non-overlap of CI and/or markedly dissimilar point estimates. 
e – Risk of bias was judged to be high. 
11 
 
Risk of bias 
Figure 2 shows a summary of the risk of bias decisions made per category for the 
included studies. Supplementary table 4 describes risk of bias for each study in detail.  
Selection bias 
An acceptable method of random sequence generation (i.e. computer generated) was 
used in 36 studies, 8 studies were judged as being at high risk of bias and the 
remaining 129 studies were judged as being at unclear risk due to insufficient 
information to determine randomisation methods. The majority of studies (n = 156) did 
not report allocation concealment and were judged as unclear. Fourteen studies were 
judged as being at low risk of bias as allocation was blinded. In 3 studies, the 
researchers were not blinded to the allocation process and we judged these studies 
as being at high risk of bias. 
Performance and detection bias  
All trials were at high risk of performance bias (i.e. blinding of participants to the 
intervention and outcomes). Lack of investigator blinding could have influenced 
measures of resting blood pressure and flow-mediated dilatation but is more likely to 
have had an impact on the motivation provided to participants during V̇O2max tests. 
The majority of studies (n = 144) were rated as unclear for detection bias (i.e. blinding 
of outcome assessor) due to insufficient information provided in the studies. Two 
studies were at high risk of detection bias, with the remaining 27 studies at low risk.  
Attrition bias 
The majority (n = 122) of studies were judged as being at low risk for incomplete 
outcome data. A further 37 studies were rated as unclear risk due to attrition rates 
>20% in one of the study groups (i.e. control or RET). Few studies were rated as high 
risk (14) due to high dropout rates or some participants being excluded from the 
analysis. 
Reporting bias 
The majority (n = 166) of studies were rated as low risk for selective reporting bias. A 
further 4 studies were classed as unclear due to a lack of description of outcome 
measures and 3 studies rated as high risk as data for some outcomes were not 
reported.  
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Publication bias 
Funnel plots were produced for all outcomes, except flow-mediated dilatation 
(supplementary Figures 1-13). All funnel plots were asymmetrical, indicating 
publication bias. 
Sensitivity analysis 
Results from the sensitivity analysis are summarised in supplementary table 9. 
Heterogeneity was reduced in 16/33 outcomes.  The most considerable reductions 
were in those outcomes with fewer studies such as short-term systolic and diastolic 
blood pressure and long-term total and high-density lipoprotein cholesterol and these 
results could alter the main findings. However, in the outcomes with more studies (e.g. 
total cholesterol, high-density lipoprotein cholesterol) it is unlikely that this sensitivity 
analysis will alter the main findings.  
GRADE analysis 
All outcomes were rated as very low or low quality evidence demonstrating that the 
estimate of effect for those outcomes is uncertain. 
 
Figure 2. Risk of bias summary. 
 
A summary of the change observed for each outcome at all durations is presented as 
mean difference and 95% CI in Figure 3. 
Resting blood pressure and heart rate 
Resting blood pressure and resting heart rate are presented in Table 3 and 
Supplementary Figures 14-17. Favourable reductions in systolic blood pressure (in the 
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range 3-5 mmHg; P ≤ 0.04) and diastolic blood pressure (in the range 1-5 mmHg; P ≤ 
0.008) were apparent after medium- and long-term term RET interventions (Table 1), 
with studies showing moderate to substantial heterogeneity (I2 range of 64-86%). 
There were non-significant effects for mean arterial pressure and resting heart rate 
after short- and medium-term RET interventions (Table 3 and  Supplementary Figures 
16-17).  
V̇O2max  
The effect of RET on V̇O2max is presented in Supplementary Figure 18. There was 
an improvement in V̇O2max with RET and moderate heterogeneity (mean difference 
2.07 [95% confidence interval 0.75, 3.39] ml/kg/min, P = 0.002; χ² = 11.35, I² = 30%, 
P = 0.18) in short-term studies (n=9; resistance arm: n = 177; control arm: n =131). In 
medium-term studies (n = 48; resistance arm: n = 767; control arm: n = 687) there was 
a significant improvement in V̇O2max with RET and substantial heterogeneity (mean 
difference 1.07 [95% confidence interval 0.38, 1.76] ml/kg/min, P = 0.002; χ² = 160.15, 
I² = 71%, P < 0.00001). In long-term studies (n = 11; resistance arm: n = 213; control 
arm: n = 186) there was a significant improvement in V̇O2max with RET (mean 
difference 1.22 [95% confidence interval 0.44, 2.0] ml/kg/min, P = 0.002; χ² = 10.22, I² 
= 2%, P = 0.42).  
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Table 3. The effects of short- (ST), medium- (MT) and long-term (LT) RET on resting blood pressure, mean arterial pressure and 
resting heart rate. 
 
*Indicates statistical significance. † Indicates favouring RET. RET – resistance exercise training, CON – control group, ST – short 
term, MT – medium term, LT – long term. 
 
 
Outcome Number of studies 
Number of participants Mean difference  
[95% CI] 
P values Heterogeneity 
RET CON 
Systolic 
blood 
pressure 
(mmHg) 
ST 4 59 57 -3.17 [-6.95, 0.6] † 0.1 χ² = 5.76, I² = 48%, P = 0.12 
MT 46 742 714 -4.02 [-5.92, -2.11] † <0.0001* χ² = 325.48, I² = 86%, P < 0.00001 
LT 8 188 178 -5.08 [-10.04, -0.13] † 0.04* χ² = 19.46, I² = 64%, P = 0.007 
Diastolic 
blood 
pressure 
(mmHg) 
ST 4 59 57 -0.72 [-3.66, 2.22] † 0.63 χ² = 8.1, I² = 63%, P = 0.04 
MT 45 721 697 -1.73 [-2.88, -0.57] † 0.003* χ² = 263.07, I² = 83%, P < 0.00001 
LT 7 177 169 -4.93 [-8.58, -1.28] † 0.008* χ² = 22.07, I² = 73%, P = 0.001 
Mean 
arterial 
pressure 
(mmHg) 
ST 3 35 32 -3.31 [-6.86, 0.25] † 0.07 χ² = 6.61, I² = 70%, P = 0.04 
MT 10 136 132 -1.57 [-4.6, 1.46] † 0.31 χ² = 97.16, I² = 91%, P < 0.00001 
Resting 
heart rate 
(bpm) 
ST 2 16 14 -2.66 [-7.55, 2.23] † 0.7 χ² = 6.95, I² = 86%, P = 0.008 
MT 35 510 467 0.35 [-1.44, 2.13] 0.69 χ² = 266.11, I² = 87%, P < 0.00001 
LT 5 74 68 -0.48 [-3.12, 2.17] † 0.72 χ² = 6.83, I² = 41%, P = 0.15 
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Flow-mediated dilatation 
Eight studies reported flow-mediated dilatation, however due to missing data, only six 
studies (resistance arm: n = 68; control arm: n = 70), all medium-term, were included 
in the meta-analysis (Supplementary Figure 19). There was a significant improvement 
in flow-mediated dilatation favouring RET (1.69 [0.97, 2.41], P < 0.0001) with low 
heterogeneity (χ² = 0.72, I² = 0%, P = 0.98). One short-term study [25] and one long-
term study [26] reported improvements in flow-mediated dilatation after RET.  
Blood biomarkers 
Blood biomarkers are presented in Table 4 and Supplementary Figures 20-27. Non-
significant effects were observed for total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol, triglycerides and C-reactive protein 
across the different study durations (Supplementary Figures 20-23 and 27). Significant 
reductions in fasted insulin (P = 0.002) and HOMA-IR (P = 0.02) were evident after 
medium-term but not long-term RET interventions. There was a significant reduction 
in fasted glucose after medium-term (P = 0.02) but not short- or long-term RET 
interventions.  
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Table 4. The effects of short- (ST), medium- (MT) and long-term (LT) RET on blood biomarkers 
* Indicates statistical significance. † Indicates favouring RET. RET – resistance exercise training, CON – control group, ST – short 
term, MT – medium term, LT – long term, HOMA-IR – insulin resistance. 
Blood marker Number of studies
Number of participants Mean difference 
[95% CI] P values Heterogeneity RET CON 
Total 
cholesterol 
(mg/dL) 
ST 3 80 66 -5.55 [-16.58, 5.48] † 0.32 χ² = 2.39, I² = 16%, P = 0.3 
MT 32 442 440 0.57 [-5.63, 6.77] 0.86 χ² = 190.82, I² = 84%, P < 0.00001 
LT 8 115 97 -8.71 [-30.83, 13.40] † 0.44 χ² = 71.91, I² = 90%, P < 0.00001 
High-density 
lipoprotein 
cholesterol  
(mg/dL) 
ST 3 80 66 0.82 [-5.40, 7.03] 0.56 χ² = 5.99, I² = 50%, P = 0.11 
MT 39 601 590 2.23 [-0.06, 4.51] † 0.06 χ² = 734.44, I² = 95%, P < 0.00001 
LT 9 179 160 2.79 [-0.69, 6.28] † 0.12 χ² = 12.33, I² = 35%, P = 0.14 
Low-density 
lipoprotein 
cholesterol  
(mg/dL) 
ST 3 80 66 -5.10 [-11.09, 0.90] † 0.1 χ² = 0.32, I² = 0%, P = 0.85 
MT 31 503 497 -2.86 [-8.77, 3.05] † 0.34 χ² = 292.46, I² = 90%, P < 0.00001 
LT 6 135 130 -3.69 [-10.99, 3.60] † 0.32 χ² = 2.39, I² = 0%, P = 0.79 
Triglycerides 
(mg/dL) 
ST 3 80 66 -3.63 [-17.45, 10.2] † 0.61 χ² = 0.14, I² = 0%, P = 0.93 
MT 37 590 575 -3.99 [-8.78, 0.8] † 0.29 χ² = 250.54, I² = 86%, P < 0.00001 
LT 6 135 130 -2.82 [-14.98, 9.33] † 0.65 χ² = 7.99, I² = 37%, P = 0.16 
Fasted insulin 
(µU/ml) 
MT 20 304 286 -0.59 [-0.97, -0.21] † 0.002* χ² = 84.86, I² = 78%, P < 0.00001 
LT 4 89 90 -0.60 [-1.93, 0.72] † 0.37 χ² = 45.43, I² = 93%, P < 0.00001 
HOMA-IR  
MT 9 96 88 -1.22 [-2.29, -0.15] † 0.02* χ² = 94.62, I² = 92%, P < 0.00001 
LT 3 38 33 -0.18 [-0.64, 0.27] † 0.6 χ² = 1.45, I² = 0%, P = 0.48 
Fasted glucose 
(mg/dL) 
ST 2 64 58 -3.39 [-6.90, 0.11] † 0.06 χ² = 1.66, I² = 40%, P = 0.2 
MT 33 499 485 -2.39 [-4.47, -0.31] † 0.02* χ² = 318.33, I² = 90%, P < 0.00001 
LT 7 135 136 -0.07 [-2.80, 2.67] † 0.96 χ² = 46.09, I² = 87%, P < 0.00001 
C-reactive 
protein (mg/L) 
ST 2 41 41 -0.43 [-1.05, 0.19] † 0.07 χ² =1.58, I² = 37%, P = 0.21 
MT 12 199 195 -0.28 [-0.72, 0.15] † 0.20 χ² = 44.57, I² = 75%, P < 0.00001 
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Sub-group analyses 
When comparing healthy young adults ≤40 years (n = 44) with healthy older adults 
≥41 years (n = 50), there was a greater magnitude of cardio-metabolic benefit from 
RET in the older populations (supplementary tables 5 and 6). There were significant 
reductions in systolic blood pressure with medium-term RET interventions for healthy 
older adults compared to healthy younger adults (-4.36 [-5.73, -2.99] mmHg, P < 
0.00001, versus -0.56 [-1.57, 0.44] mmHg, P = 0.27, respectively) (supplementary 
table 5 and 6). In the healthy older adults there were significant improvements in 
systolic blood pressure, diastolic blood pressure, mean arterial pressure, resting heart 
rate, total cholesterol, high-density lipoprotein cholesterol, triglycerides, fasted insulin, 
fasted glucose and C-reactive protein following medium-term interventions compared 
to younger adults for the same intervention duration. Significant improvements after 
long-term interventions were also apparent for diastolic blood pressure, V̇O2max, total 
cholesterol and fasted glucose in healthy older adults ≥41 years compared to younger 
adults.  
There were greatest improvements in medium-term LDL cholesterol, short- and 
medium-term V̇O2max, and short-term systolic and diastolic blood pressure among 
older adults (≥41 years) with elevated cardio-metabolic risk or cardio-metabolic 
disease (n = 42) after medium-term interventions, compared to healthy older adults. 
For example, the largest reduction in systolic blood pressure following medium-term 
RET interventions was observed in older adults ≥41 years with elevated cardio-
metabolic risk or disease (-8.80 [-9.90, -7.69] mmHg, P < 0.00001) compared to the 
healthy older adults (-4.36 [-5.73, -2.99] mmHg, P < 0.00001).  
Adverse events 
One hundred and twenty-three RCTs (71%) did not report the occurrence of adverse 
events. Fifty studies (29%) reported information on adverse events and 17 of these 
reported that no adverse events occurred. Of the 50 studies reporting adverse events, 
16 studies reported more than one adverse event occurring. Musculoskeletal injuries 
(e.g. lower back pain, knee pain) as a result of the intervention were reported in 20 
studies (n = 20/50; 40%), with more than one adverse event being reported in 15 of 
the 20 studies. Two studies (4%) detailed discomfort and muscle soreness related to 
RET. Illness or injury unrelated to RET were reported in seven (14%) studies. Three 
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studies (6%) reported that participants suffered injuries but the details and whether 
they were related to the intervention, was unclear. Syncope, possibly related to the 
intervention, was reported in three studies (6%). Cardiac issues (e.g. myocardial 
infarction, angina) thought to be unrelated to the RET were reported in four (8%) 
studies. Respiratory problems, unrelated to the intervention, were reported in two (4%) 
and hypoglycaemia in a further two (4%) studies. Four studies (8%) identified 
participants who underwent elective surgery unrelated to the study. Five studies (10%) 
reported a newly diagnosed condition or change in medication. Other adverse events 
reported only once included death (car crash), cerebral stroke, abdominal hernia and 
deep vein thrombosis; these were not associated with RET. Personal or professional 
issues resulting in withdrawal from the programme were reported in 5 (10%) studies. 
 
DISCUSSION 
Resistance exercise training had a positive impact on cardio-metabolic health, via 
improvements in resting blood pressure, V̇O2max and blood biomarkers of cardio-
metabolic risk. These improvements were most convincing for medium-term (7-23 
weeks) interventions, which is likely to reflect the higher volume of published studies 
compared to short- (< 6 weeks) and long-term ( 24 weeks) intervention durations. 
Relatively few studies have primarily investigated the cardio-metabolic health benefits 
of RET in clinical populations, particularly those at elevated risk of cardiovascular 
events. There is limited evidence of adverse events associated with RET with only 
12% of studies included in the review reporting musculoskeletal injuries. Other studies 
reported transient levels of muscle soreness following RET, which is common after 
unaccustomed muscular exercise [27-29]. Therefore, we suggest that RET is a safe 
exercise option for both healthy and clinical populations. 
There was a positive effect of RET on systolic and diastolic blood pressure. The 
reductions observed are of similar magnitude to those after aerobic exercise 
interventions [30-33], and could suggest a dose-response relationship for 
interventions of varying durations. Furthermore, given that hypertension is a global 
cause of mortality [34], the pronounced effects of RET on blood pressure outcomes in  
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Figure 3. (A) Short-
term, (B) medium-term, (C) long-term effects of resistance exercise training as 
standardised mean difference and 95% CI. SBP - systolic blood pressure, DBP - 
diastolic blood pressure, MAP - mean arterial pressure, VO2max - maxium oxygen 
consumption, FMD - flow mediated dilatation, HDL-Chol - high density lipoprotein 
cholesterol, LDL-Chol - low density lipoprotein cholesterol, HOMA-IR - insulin 
resistance, CRP - c-reactive protein. 
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older populations observed in our subgroup analyses suggest that RET could be an 
effective non-pharmacological strategy for the prevention and/or control of 
hypertension in older adults who are at elevated cardio-metabolic risk. 
The effect of RET on mean arterial pressure and resting heart rate was not statistically 
significant. Although resting heart rate may be less sensitive to change after RET, the 
lack of effect on mean arterial pressure (particularly for medium-term studies) could 
be due to few studies reporting mean arterial pressure in comparison to systolic or 
diastolic blood pressure. Additionally, diastolic blood pressure has a greater influence 
on mean arterial pressure than systolic blood pressure and, due to the less 
pronounced effect of RET on diastolic blood pressure, this could have impacted upon 
the significance of mean arterial pressure.  
Low cardiopulmonary fitness has an indirect effect on cardiovascular disease risk and 
is partially (40-60%) mediated by cardiovascular risk factors including hypertension, 
hypercholesterolemia, obesity and fasting glucose [35]. Therefore, the beneficial 
effects of RET on V̇O2max is important. Traditionally, RET has not been used to 
provide a stimulus for improving cardiopulmonary exercise capacity, however our 
findings suggest that RET may be a reasonable choice for improving this health 
outcome. Improvements in V̇O2max after RET were modest (short-term: 2.38 [0.76, 
4.00] ml/kg/min; medium-term: 1.13 [0.50, 1.76] ml/kg/min; long-term: 1.23 [0.6, 1.87] 
ml/kg/min). However, larger effects were observed for older adults at elevated cardio-
metabolic risk. This is clinically important since it suggests that RET may contribute to 
reducing the risk of cardiovascular morbidity and mortality in high risk populations [36]. 
On the other hand, it is also possible that those who participated in RET also increased 
their participation in aerobic activity. Exercise training outside of RET interventions 
was generally not monitored and may account for some of the change in V̇O2max after 
RET.  
Endothelial dysfunction is associated with cardiovascular disease and the ageing 
process. Endothelial dysfunction is linked to a decrease in nitric oxide availability, 
which can be improved through exercise [37]. A deterioration in flow-mediated 
dilatation of approximately 1% is associated with a 13% increased risk of future 
cardiovascular events [38, 39]. We found improvements in endothelial function (flow-
mediated dilatation) with RET programmes that lasted 7-23 weeks. This is likely to 
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result from shear stress-induced adaptations in nitric oxide metabolism resulting from 
muscular contractions, resting heart rate and blood pressure changes during RET [26]. 
Shear-stress induced adaptations may not be restricted to blood vessels within the 
active skeletal muscles, as exercise programmes that are performed predominantly 
with the legs induce improvements in brachial artery flow-mediated dilatation [40]. 
Therefore, RET may be an effective stimulus for improving flow-mediated dilatation, 
potentially reducing the risk of cardio-metabolic disease. 
The most favourable changes in blood biomarkers were apparent in short- and 
medium-term studies in the pooled analysis. The lower number of longer-term studies 
may have reduced the level of statistical power required to detect significant changes. 
We found greater reductions in low-density lipoprotein cholesterol, triglycerides and 
fasted glucose among older adults. There were also significant reductions in C-
reactive protein after short- and medium-term RET among older adults at elevated 
cardio-metabolic risk (Table 4 and Supplementary Table 7). Reductions in C-reactive 
protein, fasted glucose and insulin, and HOMA-IR could have been mediated by the 
effect of RET on body composition, including an increase in skeletal muscle mass and 
reduction in fat mass, and the resulting impact on adipokine secretion [15, 41], insulin 
sensitivity [42] and glucose transport [43, 44]. These improvements in metabolic 
functioning following RET could have important clinical implications for the prevention 
and treatment of metabolic syndrome, type 2 diabetes mellitus and cardiovascular 
disease [41, 32, 45, 46]. 
Future studies on RET interventions should monitor or control for the potential 
confounding influence of aerobic exercise outside of the intervention. It is unclear 
whether improvements in V̇O2max after RET are more attributable to the 
cardiopulmonary stimulus of RET leading to improved oxygen transport (via increased 
cardiac stroke volume) or metabolic adaptations resulting in improved utilisation of 
oxygen at the level of skeletal muscle. Improvements in V̇O2max following medium- to 
long-term programmes of aerobic exercise training tend to be greater and mainly 
reflect an increase in cardiac stroke volume in previously untrained individuals [47, 
48]. The relative importance of, and potential to maximise central, systemic and 
peripheral adaptations, by altering the characteristics of RET (e.g. sets, repetitions, 
rest etc.) warrants further research.  Furthermore, additional high-quality research is 
also required to formulate the optimal design of a RET programme to promote 
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cardiovascular health and risk factor management in middle-aged and clinical 
populations. 
Limitations  
The main findings of this systematic review need to be considered in the context of 
some key limitations, including restricting the search to two electronic databases, 
language bias and unexplained statistical heterogeneity for some of the analyses. 
Publication bias was also evident, and is probably attributable to inadequate data 
analysis, poor methodological quality and/or varying sample sizes of included studies. 
It is unlikely that selective outcome reporting influenced the funnel plots as 90.6% of 
the studies were rated as low risk for this outcome. Additionally, poor methodological 
quality of some of the included studies could have affected the estimates of the 
outcomes. Although all the included studies were RCTs, few studies adequately 
reported the randomisation process (n = 36), allocation concealment (n = 14), or 
blinding of outcome assessment (n = 27). Therefore, many studies were rated as 
unclear bias in multiple categories and this may have contributed to the lack of 
reduction in heterogeneity in the sensitivity analyses. Additionally, some data were not 
pooled due to lack of access to the mean (SD) scores.  
Reporting must improve, as many studies had incomplete descriptions of RET 
programmes and progression, small sample sizes, inadequate documentation of 
adherence and lacked detail regarding the timing of blood sampling in relation to the 
last bout of exercise (potentially influencing circulating levels of blood biomarkers). 
Improved reporting of trials may also improve the quality of evidence, as all outcomes 
in this review were graded as either very low or low quality, and higher-quality reporting 
of outcomes may alter the effect estimates. Authors should follow guidelines when 
reporting trials such as the TIDieR checklist and guide [49].  
Studies of varying duration are needed, as the majority included in our systematic 
review involved medium-term interventions. In addition, data analyses were often 
based only on participants who successfully completed the training intervention, rather 
than applying an intention to treat analysis. This could have altered the study results 
[23, 50]. Finally, cardiorespiratory fitness levels of participants prior to a RET 
intervention is likely to influence training-induced adaptations and this should be 
considered in future research.  
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CONCLUSION  
RET was a safe and effective exercise modality for inducing improvements in resting 
blood pressure, flow-mediated dilatation, blood biomarkers of cardio-metabolic risk 
and cardiopulmonary fitness in adults. The effects were more pronounced in older 
adults (≥41 years) and those with elevated cardio-metabolic risk or disease. 
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SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
WHAT ARE THE NEW FINDINGS? 
 The results suggest that RET improves several 
cardiometabolic risk factors; however, the quality of the 
evidence was low and there were no data on hard 
clinical end-points. 
 Improvements in cardiometabolic risk factors were more 
pronounced in individuals with elevated cardiometabolic 
risk or disease when compared with younger healthy 
adults. 
 Few adverse events were reported, suggesting that 
RET is safe. 
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Table 1. Search Strategy 
Database Search Strategy 
MEDLINE 1. ((strength$ or resist$ or weight$) adj3 training).tw. 
2. (progressive resist$).tw. 
3. or/1-2 
4. Exercise/ 
5. Exercise Therapy/ 
6. exercise$.tw. 
7. or/4-6 
8. (Resist$ training or strength$).tw. 
9. and/7-8 
10. or/3,9 
11. randomized controlled trial.pt 
12. controlled clinical trial.pt. 
13. Randomized Controlled Trials/  
14. Random Allocation/ 
15. Double Blind Method/ 
16. Single Blind Method/ 
17. or/11-16 
18. Animals/ not Humans/ 
19. 17 not 18 
20. and/10,19 
The Cochrane 
Library (Wiley) 
#1 ((strength* or resist* or weight*) NEAR/3 training):ti,ab,kw 
#2 (progressive resist*):ti,ab,kw 
#3 #1 OR #2 
#4 MeSH descriptor Exercise, this term only 
#5 MeSH descriptor Exercise Therapy, this term only 
#6 (exercise*):ti,ab,kw 
#7 (#4 OR #5 OR #6) 
#8 (resist* or strength*):ti,ab,kw 
#9 (#7 AND #8) 
# 10 (#3 OR #9) 
 
 
 
 
  
 
Table 2. Study characteristics 
Author & 
year 
Country Population 
Duration & 
frequency 
Intervention 
Timing of 
outcomes 
Funding & conflicts of interest 
Ades et al. 
1996 
USA 
RT = 69.9 ± 4 yrs 
CON = 70.7 ± 5 yrs 
Male and female 
Healthy elderly 
12 weeks 
3 d per 
week 
Supervision not reported 
Free weights and weight machines 
3 sets of 8 reps at 50% 1RM with 
progression to 80% by week 9 
Baseline 
and 12 
weeks 
Grants from National Institute of 
Health and General Clinical 
Research Centres. 
Afshar et al. 
2010 
Iran 
RT = 51 ± 16.4 yrs  
AT = 50.7 ± 21.1 yrs 
CON = 53 ± 19.4 yrs 
Males  
Haemodialysis 
8 weeks Supervised by a physician 
Ankle weights 
2 sets of 8 reps progressed to 3 sets 
 
Baseline 
and 8 
weeks 
 
Ahmadizad 
et al. 2007 
Iran 
RT = 40.9 ± 3.2 yrs  
AT = 41.3 ± 5.1 yrs  
CON = 38.6 ± 3.2 yrs 
Male  
Sedentary obese 
12 weeks 
3 d per 
week 
 
Supervision not reported 
Circuit resistance training 
4 sets of 12 maximal reps at 11 stations 
50–60% of 1RM in each station 
 
Baseline 
and 12 
weeks 
Tarbiat Moallem University of 
Sabzevar in Iran. 
Ahmadizad 
et al. 2014 
Iran 
Total cohort 23.4 ± 0.6 yrs 
Male 
Sedentary overweight 
8 weeks 
3 d per 
week 
 
Supervised 
Free weights, weight machines and body 
weight 
1-2 weeks: 1 set of 10 reps  
3-8 weeks: 2–3 sets of 20–30 reps 
NP: constant moderate intensity  
DUP: rotated loading 
LP: volume was decreased and the training 
intensity was increased each week 
Baseline 
and 8 
weeks 
 
Almenning et 
al. 2015 Norway 
Total cohort 27.2 ± 5.5 yrs 
Females  
Polycystic ovary syndrome 
10 weeks 
3 d per 
week 
Supervised by an exercise physiologist at 
least 1 session a week 
3 sets of 10 reps at 75% 1RM 
Baseline 
and 10 
weeks 
The Norwegian Fund for 
Research in Sports Medicine. 
Anderson et 
al. 2004 
USA 
RT = 26.4 ± 7.5 yrs 
AT = 20.9 ± 2.4 yrs 
CON = 26.6 ± 6.5 yrs 
Males  
Healthy sedentary  
6 weeks 
3 d per 
week 
 
Supervision not reported 
Free-weight and machine exercises 
2 sets of 10-15 reps 
 
Baseline 
and 6 
weeks 
 
Andersen et 
al. 2008 
Denmark 
RT = 44 ± 9 yrs  
Fitness Training = 45 ± 9 
yrs  
CON = 42 ± 8 yrs 
Females  
Trapezius myalgia 
10 weeks 
3 d per 
week 
 
Supervised 
Free-weight and machine exercises 
3 sets 
Intensity progressively increased from 
12RM to 8RM  
Baseline 
and 10 
weeks 
Grants from Danish Medical 
Research Council and the 
Danish Rheumatism 
Association. 
Andersen et 
al. 2014 
Denmark 
Total cohort = 68.2 ± 3.2 
yrs 
Males  
Healthy elderly 
16 weeks 
2 d per 
week 
Supervised 
Free-weight and machine exercises 
0-4 weeks: 3 sets of 16-20 reps  
5-8 weeks: 3 sets of 12 reps  
Baseline 
and 16 
weeks 
Supported by the FIFA Medical 
Assessment and Research 
Centre, The Danish Ministry of 
9-12 weeks: 3 sets of 10 reps  
13–16 weeks: 4 sets of 8 reps  
Culture, and Nordea-fonden, 
Denmark. 
Andersen et 
al. 2016 
USA 
Total cohort = 68.1 ± 2.1 
yrs  
Healthy elderly 
36 weeks 
2 d per 
week 
Supervised 
Free weight, weight machines and body 
weight 
0-4 weeks: 3 sets of 16–20RM 
5-8 weeks: 3 sets of 12RM  
9-12 week: 3 sets of 10RM  
13-52 weeks: 4 sets of 8RM  
Baseline 
and 36 
weeks 
Supported by the FIFA-Medical 
Assessment and Research 
Centre (Project 31964). The 
Danish Ministry of Culture 
(Kulturministeriets Udvalg for 
Idrætsforskning) (TKIF 2010-
027), and Nordea-fonden (02-
2011-4360).  
Arora et al. 
2009 
India 
RT = 49.6 ± 5.2 yrs  
AT= 52.2 ± 9.3 yrs 
CON = 58.4 ± 1.8 yrs 
Male and female  
Type 2 diabetes 
8 weeks 
2 d per 
week 
 
Supervised 
3 sets of 10 reps at 60-100% 1RM 
Baseline 
and 8 
weeks 
Grant from University Grants 
Commission, Delhi, India. 
Asad et al. 
2012 
Iran 
RT = 21 ± 1.6 yrs  
AT = 22 ± 0.9 yrs 
Concurrent = 21.4 ± 2.1 yrs 
CON = 21.4 ± 1.1 yrs 
Male  
Healthy sedentary  
8 weeks 
3 d per 
week 
 
Supervision not reported 
Free weights and weight machines 
3 sets of 10-15 reps 
Weeks 2-8: first set for 10-12 reps, 8-10 
reps for second set and 4-8 reps for third 
set 
Baseline 
and 8 
weeks 
 
Augusto 
Libardi et al. 
2012 
Brazil 
RT males = 47 ± 4.5 yrs 
RT females = 53.7 ± 3.7 yrs 
CON males = 49.5 ± 5.6 yrs 
CON females = 51.2 ± 6.4 
yrs 
Males and females 
Healthy sedentary 
16 weeks 
3 d per 
week 
 
Supervision not reported 
Free-weight, machine exercises and body 
weight 
3 sets of 10 reps 
9-16 weeks: 8 reps 
Baseline 
and 16 
weeks 
Supported by Conselho 
Nacional de Desenvolvimento 
Científico e Tecnológico 
Azarbayjani 
et al. 2014 
Iran 
RT = 23.1 ± 1.4 yrs 
AT = 23.3 ± 1.3 yrs 
Concurrent = 22.9 ± 1.7 yrs 
CON = 22.9 ± 1.7 yrs  
Males 
Healthy sedentary 
12 weeks 
3 d per 
week 
 
Supervision not reported 
Free-weight and machine exercises 
3 sets of 10 reps at 70% 1RM 
 
Baseline 
and 12 
weeks 
Grant (90084702) from the 
Islamic Azad University, Central 
Tehran Branch grants 
commission. 
Badrov et al. 
2013 
Canada 
IHG3 = 23 ±4 yrs  
IHG5 = 27 ±6 yrs  
CON = 24 ± 8 yrs 
Females 
Healthy sedentary 
8 weeks 
IHG3 - 
every other 
day  
IHG5 - five 
consecutive 
days 
Supervision for 2 sessions a week 
Isometric hand grip at 30% MVC 
Baseline, 4 
and 8 
weeks 
Supported by the University of 
Windsor (810043; 809264; 
808316; CLM), the Canadian 
Institutes of Health Research, 
Heart and Stroke/Richard Lewar 
Centre of Excellence 
Postdoctoral Fellowship, and an 
Ontario Graduate Scholarship. 
Baldi & 
Snowling 
2013 
New Zealand 
RT= 46.5 ± 2.1 yrs  
CON = 50.1 ± 1.3 yrs 
Females 
10 weeks 
3 d per 
week 
Supervised 
1-2 circuits of 12 reps at 10RM (upper 
body) or 15RM (lower body) 
Baseline 
and 10 
weeks 
 
Type 2 diabetes 
DeBarros et 
al. 2010 
Brazil 
RT =  31.8 ± 4.9 yrs 
CON = 32.4 ± 5.4 yrs 
Female 
Type 2 diabetes 
24-34 
weeks  
3 d per 
week 
 
Supervised by the researcher for 1 session 
a week 
Elastic resistance band circuit 
Exercise intensity was controlled using a 
perceived exertion scale. Subjects advised 
to maintain an exercise intensity close to 5 
or 6, which corresponds to a “somewhat 
heavy”.  
Baseline 
and 24 
weeks 
Supported by Coordenação de 
Aperfeiçoamento de Pessoal de 
Nível Superior with master’s 
fellowship grant. 
Beck et al. 
2013 
Beck et al. 
2013 
USA 
RT = 21.1 ± 2.5 yrs  
AT = 20.1 ± 1.1 yrs  
CON = 21.6 ± 2.9 yrs  
Normotensive CON = 21.6 
± 2.7 yrs  
Male and female young 
Pre-hypertensives 
 
RT = 21.1 ± 0.6 yrs  
AT = 20.1 ± 0.9 yrs 
CON = 21.6 ± 0.8 yrs  
Normotensive CON = 21.6 
± 0.7 yrs 
Male and female 
Pre-hypertensives 
8 weeks 
3 d per 
week 
 
Supervision not reported 
Weight machines 
2 sets of 8–12 reps to volitional fatigue 
 
Weight machines 
2 sets of 8–12 reps to volitional fatigue 
 
Baseline 
and 8 
weeks 
Supported, in part, by a National 
Institutes of Health pre-doctoral 
training grant (NIH 5-T32-
HL083810-04) awarded by the 
University of Florida 
Hypertension Centre.  
 
Supported, in part, by a National 
Institutes of Health predoctoral 
training grant (NIH 5-T32-
HL083810-04) awarded to 
D.T.B. by the University of 
Florida Hypertension Centre. 
Bell et al. 
2000 
Canada 
Total cohort = 22.3 ± 3.3 
yrs 
Male and female 
Physically active 
12 weeks 
3 d per 
week 
Supervision not reported 
Free-weight and machine exercises 
2-6 sets of 4-12 reps  
Baseline, 6 
and 12 
weeks 
 
Beltran Valls 
et al. 2014 
Italy 
RT = 72 ± 1 yrs 
CON = 72 ± 1 yrs 
Male and female 
Healthy elderly 
12 weeks 
2 d per 
week 
Supervised 
Weight machines 
1-2 weeks:  4 sets of 15 reps at 40–50 % 
1RM  
3-12 weeks: 3–4 sets of 10–12 reps at 70 
% of baseline 1RM 
Baseline 
and 12 
weeks 
Grants from the University of 
Rome “Foro Italico” (Research 
2009) to D. C. The Lazio 
Regional Municipality 
(Agreement CRUL-Lazio n. 
12650/2010) supported the post-
doc scholarship to ID. 
Bertuzzi et 
al. 2013 
Brazil 
RT = 31 ± 5 yrs 
RT with WBV = 34 ± 6 yrs 
CON = 33 ± 7 yrs 
Sex not reported. 
Long-distance runners 
6 weeks 
2 d per 
week 
Supervised 
Weight machines 
1–2 weeks: 3 sets at 8-10RM 
3–4 weeks: 4 sets at 6-8RM 
5–6 weeks: 6 sets at 4–6RM  
Baseline 
and 6 
weeks  
Post-doctoral grant São Paulo 
Research Foundation (FAPESP: 
08-50934-1) and master 
scholarships from São Paulo 
Research Foundation (FAPESP: 
2010/13913-6 and 2011/02769-
4, respectively). 
Bishop & 
Jenkins 1996 Australia 
Only report cohort was 17-
24 yrs 
Males 
6 weeks 
3–4 d per 
week 
Supervised 
Weight machines 
3-6 sets of 1-3 or 12-15 reps 
Baseline 
and 6 
weeks  
 
Physically active  
Bishop et al. 
1999 
Australia 
Only report cohort was 18-
42 yrs 
Female  
Cyclists 
12 weeks 
2 d per 
week 
Supervised 
Weight machines 
5 sets to failure at 2-8RM 
Baseline, 6 
and 12 
weeks 
 
Boardley et 
al. 2007 
USA 
RT = 74.1 ± 6.2 yrs 
Combined = 75.3 ± 6 yrs 
AT = 73.2 ± 6.6 yrs 
CON = 75.9 ± 7.7 yrs 
Male and female 
Healthy elderly 
16 weeks 
3 d per 
week 
 
Supervised by project staff for 2 sessions a 
week 
Elastic resistance bands 
1-2 weeks: 1 set of 10 reps 
3-16 weeks: 2 sets of 12 reps 
Theraband colour was changed so that it 
provided sufficient resistance to produce 
mild fatigue at the final rep 
Baseline, 8 
and 16 
weeks 
Funded by the National Institute 
for Nursing Research grant 
#R01 NR04929. The Hygenic 
Corporation supplied the Thera-
Band but had no other role in 
the study. 
Borges & 
Carvalho 
2014 
Brazil 
RT = 64.1 ± 12.5 yrs 
CON = 67.8 ± 9 yrs 
Male and female 
COPD 
Completed 
a minimum 
of 3 
sessions 
Supervised 
Free weights and weight machines 
2 sets of 9 reps  
Initial load was 80% 1RM and adjusted in 
subsequent sessions based on symptoms, 
Borg Dyspnea Scale scores, and patient 
fatigue 
Evaluated 
on the 
second day 
in hospital, 
at 
discharge, 
and 30 
days post 
discharge 
 
Brentano et 
al. 2008 
Brazil 
Age not reported 
Female 
Post-menopausal 
24 weeks 
3 d per 
week 
 
Supervision not reported 
Free-weight and machine exercises 
RT circuit: 2-3 sets of 10-20 reps at 45-60% 
1RM  
RT: 2-4 sets of 6-20 reps at 45-80% 1RM 
Baseline, 8, 
16 and 24 
weeks 
 
Brito et al. 
2013 Brazil 
Age not reported. 
Male and female HIV/AIDS  
24 weeks. 
3 d per 
week 
Supervised 
Free-weight and machine exercises 
3 sets of 8-10 reps at 80% 1RM  
Baseline 
and 24 
weeks  
 
Broeder et 
al.1992 
USA 
Only report cohort 18-35 
years 
Males 
Physically active 
12 weeks 
4 d per 
week 
 
Supervised 
Free-weight and machine exercises 
1-2 weeks: 10-12 reps 
3-12 weeks: 10-12 reps on the first set, 8-
10 reps on the second set, and 6-8 reps on 
the third set 
Baseline 
and 12 
weeks 
 
Brooks et al. 
2007 
USA 
RT = 66 ± 2 yrs 
CON = 66 ± 1 yrs 
Males and females 
Type 2 diabetes 
16 weeks 
3 d per 
week 
 
Supervision not reported 
Weight machines 
3 sets of 8 reps  
1-9 weeks: 60% 1RM 
10-14 weeks: 70-80% 1RM 
Baseline 
and 16 
weeks 
Funded, in part, by the 
Brookdale Foundation, the 
USDA ARS agreement 58-1950-
9-001, the NIH General Clinical 
Research Center M01 
RR000054, and the International 
Life Sciences Institute North 
America. 
Buchner et 
al. 1997 
USA 
RT = 74 yrs 
AT = 75 yrs 
AT + RT = 75 yrs 
CON = 75 yrs 
Male and female 
Healthy elderly 
24-26 
weeks 
3 d per 
week 
Supervised 
Weight machines  
2 sets of 10 reps with the first set at 50-60% 
1RM and the second set 75% 1RM 
Baseline 
and 24  
weeks 
Follow up 
at 28 
weeks 
Grants from the National 
Institute on Aging (UO1 
AG09095), Centres for Disease 
Control and Prevention (R48 
CCR002181), and the 
Department of Veterans Affairs. 
Camargo et 
al. 2008 
Brazil 
RT = 29 ± 3 yrs 
AT = 29 ± 4 yrs   
CON = 30 ± 4 yrs 
Males 
Healthy sedentary 
12 weeks 
3 d per 
week 
Supervised 
Weight machines 
3 sets of 15 reps at 60% of 1RM 
Baseline 
and 12 
weeks 
Partially supported by a grant 
from FIPE-Hospital de Clinicas 
de Porto Alegre and FAPICC. 
Castaneda et 
al.  2002 
USA 
RT = 66 ± 2 yrs 
CON = 66 ± 1 yrs 
Male and female 
Type 2 diabetes  
16 weeks 
3 d per 
week 
 
Supervision not reported 
3 sets of 8 reps 
Weight machines 
1-8 weeks: 60-80% of baseline 1RM 
10-14 weeks: 70-80% of mid-study 1RM 
Baseline 
and 16 
weeks 
Funded, in part, by Brookdale 
foundation in U.S. Department 
of Agriculture, the National 
Institutes of Health Clinical 
Research Centre and the 
International Life Sciences 
Institute, North America. 
Christensen 
et al. 2014  
Denmark 
RT = 34.4 ± 7.6 yrs 
CON= 35.8 ± 8.9 yrs 
Male 
Disseminated  
germ cell cancer 
9 weeks 
3 d per 
week 
Supervised 
1-2 weeks: 3 sets of 15 reps at 15RM 
3-9 weeks: 4 sets of 10 reps at 10-12RM 
Baseline 
and 9 
weeks 
Supported by Copenhagen 
University Hospital, the Beckett 
Foundation and the Centre for 
Integrated Rehabilitation of 
Cancer Patients. 
Colado et al. 
2009 
Spain 
RT = 54 ± 2.8 yrs 
Aquatic = 54.7 ± 2 yrs 
CON = 52.9 ± 1.9 yrs 
Female 
Post-menopausal 
24 weeks Supervised 
Free-weight, machine and body weight 
exercises 
1-12 weeks: 8 exercise circuit, 1 set of 20 
reps with 30 sec active rest between sets, 1 
set upper body, 2 sets lower body.          
12-24 weeks: 10 exercise circuit, 1 set of 20 
reps  
Baseline 
and 24 
weeks 
Funding (PMAFI-PI-01/1C/04) 
from the Research Funds 
Program of the Catholic 
University San Antonio in Murcia 
(Spain). 
Conceição et 
al. 2013 
Brazil 
RT = 53.4 ± 4 yrs 
CON = 53 ± 5.7 yrs 
Females 
Post-menopausal 
16 weeks 
3 d per 
week 
Supervision not reported 
Free-weight, machine and body weight 
exercises 
1-8 weeks: 3 sets of 10 reps at 10RM with 
60 s rest between sets 
9-16 weeks: 3 sets of 8 reps at 8RM with 90 
s rest between sets 
Baseline 
and 16 
weeks 
Funding from the São Paulo 
Research Foundation (FAPESP) 
for financial support 
(2012/09709-0). 
Courneya et 
al. 2007 
Courneya et 
al. 2010 Canada 
RT= 49.5 yrs  
AT = 49 yrs 
Control = 49 yrs 
Females 
Breast cancer 
18 weeks  
Not 
reported 
Supervised 
Weight machines 
2 sets of 8-12 reps at 60% to 70% 1RM 
Baseline, 9 
(only for 
subjective 
measures) 
and 18 
weeks  
None reported  
 
Grant from the Canadian Breast 
Cancer Research Alliance. Also  
supported by a Doctoral 
Research Award from the 
Canadian Institutes of Health 
Research, the Canada 
Research Chairs Program, a 
Research Team Grant from the 
National Cancer Institute of 
Canada with funds from the 
Canadian Cancer Society and 
the National Cancer Institute of 
Canada Canadian Cancer 
Society Socio-behavioural 
Cancer Research Network and a 
New Investigator Award from the 
Heart and Stroke Foundation of 
Canada. 
Croymans et 
al. 2013 
USA 
RT = 21.5 yrs 
Control = 22 yrs 
Male 
Sedentary obese 
12 weeks 
3 d per 
week 
 
Supervised 
Free-weight, machine and body weight 
exercises 
1-2 weeks: 2 sets of 12–15 reps at 100% of 
estimated 12–15RM 
3–7 weeks: 3 sets of 8–12 reps, at 100% of 
8–12RM 
8–12: weeks: 6–8 reps at 6–8RM 
Baseline 
and 12 
weeks 
Supported by the American 
Heart Association (BGIA no 
0765139Y to CKR), the National 
Heart, Lung and Blood Institute 
(P50 HL105188 to CKR) and the 
National Centre for Advancing 
Translational Sciences through 
UCLA CTSI Grant 
UL1TR000124 RAH and the 
American Heart Association 
(10SDG305006). 
Davidson et 
al. 2009 
USA 
FEMALES:  
RT = 67.6 ± 4.2 yrs 
AT = 69.1 ± 6.5 yrs 
Combined = 66.5 ±   5.3 yrs 
CON = 66.7 ± 3.7 yrs 
MALES:  
RT = 67.4 ± 6 yrs  
AT = 68.8 ± 6 yrs 
Combined = 67.1 ± 5 yrs 
CON = 67.4 ± 3.8 yrs 
Male and female 
Sedentary obese  
24 weeks 
3 d per 
week 
 
Supervision not reported 
Free-weight, machine and body weight 
exercises 
1 set 
Each exercise was performed until volitional 
fatigue 
Baseline 
and 24 
weeks 
Supported by research grant MT 
13448 from the Canadian 
Institutes of Health Research. 
DeLima et al. 
2012 
Brazil 
RT linear periodization = 
25.2 ± 4.4 yrs  
RT undulating periodization 
= 27.4 ± 2.8 yrs 
CON = 23.4 ± 1.3 yrs 
Female 
Healthy sedentary 
12 weeks 
3 d per 
week 
Supervised 
Free-weight, machine and body weight 
exercises 
3 sets until failure 
RT linear: 3 sets of 30RM, in the second 
week 3 sets of 25RM, in the third week 3 
sets of 20RM and in the fourth week 3 sets 
of 15RM 
RT undulating: weeks 1, 3, 5, 7, 9 and 11, 
participants trained on days 1 and 2 with 3 
Baseline 
and 12 
weeks 
 
sets of 30RM and on days 3 and 4 with 3 
sets of 25RM. Weeks 2, 4, 6, 8, 10 and 12, 
participants trained on days 1 and 2 with 3 
sets of 20RM and on days 3 and 4 with 3 
sets of 15RM.  
DeSouza et 
al. 2014 
Brazil 
RT = 25.9 ± 6.4 yrs 
Interval = 24 ± 7.5 yrs 
Concurrent = 22.5 ± 3.9 yrs 
CON = 22.1 ± 2.4 yrs 
Male 
Physically active 
8 weeks 
2 d per 
week 
Supervision not reported 
3-5 sets of 6-12RM 
Baseline 
and 8 
weeks 
 
Deibert et al. 
2011 
Germany 
RT = 55.5 ± 4.8 yrs  
RT + supplement = 55.9 ± 
3.5 yrs 
CON = 55.8 ± 5.5 yrs 
Male 
Healthy sedentary 
12 weeks 
2 d per 
week 
 
Supervised 
Weight machines 
1–4 weeks: 25 reps  
5–9 weeks: 15 reps  
10-12 weeks: 10 reps  
Baseline 
and 12 
weeks  
Grants from Almased Wellness 
Corp. 
DeVallance 
et al. 2016 
USA 
RT = 51 ± 3 yrs 
CON = 44 ± 3 yrs 
Male and female 
Metabolic syndrome 
8 weeks 
3 d per 
week 
Supervision not reported 
Weight machines 
3 sets of 8-12 reps 
1–2 weeks: 60% of 1RM 
3–4 weeks: 70% of 1RM 
5–6 weeks: 80% of 1RM 
7–8 weeks: 85% of 1RM  
Baseline 
and 8 
weeks 
Supported in part by the 
American Heart Association 
Grant 11CRP7370056, National 
Heart, Lung, and Blood Institute 
Grant T32-HL-090610, and 
National Institute of General 
Medical Sciences of the National 
Institutes of Health under Award 
U54-GM-104942 and 1P20 
GM109098, STEM Mountains of 
Excellence Fellowship. 
Donges et al. 
2010 
Australia 
Age not reported. 
Male and female 
Healthy sedentary 
10 weeks 
3 d per 
week 
 
Supervised 
Weight machine exercises  
10RM that is reported to approximate with 
75% of a 1RM 
Baseline 
and 10 
weeks 
Funded by Charles Sturt 
University. 
Dunstan et 
al. 1998 
Australia 
RT Circuit = 50.3 ± 7.7 yrs 
CON = 51.1 ± 7.6 yrs 
Male and female 
Type 2 diabetes 
8 weeks 
3 d per 
week 
Supervised 
Free-weight, machine and body weight 
exercises 
1-2 weeks: 2 sets of 10-15 reps at 50–55% 
1RM  
3-8 weeks: 3 sets of 10-15 reps at 50–55% 
1RM  
Baseline 
and 8 
weeks 
Supported by a National Health 
and Medical Research Council 
program grant ‘Studies in 
hypertension and vascular 
disease’. 
Edge et al. 
2006 
Australia 
Total cohort = 18 ± 1 yrs 
Female 
Physically active 
5 weeks Supervision not reported 
Free weights and machines 
1-2 weeks: 2-3 sets of 15-20 reps 
3-5 weeks: 3-5 sets of 15-20 reps 
Set 1 at 70% 3RM; set 2 at 60% 3RM; sets 
3–5 at 50% 3RM   
Baseline 
and 5 
weeks 
 
Egana et al. 
2010 
Ireland 
RT = 69 ± 5 yrs 
CON = 64 ± 4 yrs 
Female 
Healthy elderly 
12 weeks 
2 d per 
week 
 
Supervised 
Therabands 
2 sets at 100% 10RM  
Baseline 
and 12 
weeks 
 
Elliott et al. 
2002 
UK 
RT = 58 ± 4 yrs 
CON = 53 ± 3 yrs 
Female 
Post-menopausal 
8 weeks 
3 d per 
week 
Supervision not reported 
3 sets of 8 reps at 80% 10RM  
Baseline 
and 8 
weeks  
Follow-up 
at 16 
weeks 
 
Fahlman et 
al. 2002 
USA 
RT = 73 ± 3 yrs 
AT = 76 ± 5 yrs  
CON = 74 ± 5 yrs 
Female 
Healthy elderly 
10 weeks 
3 d per 
week 
Supervision not reported 
Weight machines 
3 sets of 8 reps at 8RM 
Baseline 
and 10 
weeks 
 
Fatouros et 
al. 2005 
Greece 
RT low intensity = 71.1 ± 
3.6 yrs 
RT mod intensity = 69.7 ± 
3.8 yrs 
RT high intensity = 70.8 ± 
2.8 yrs 
CON = 69.8 ± 5.1 yrs 
Male 
Sedentary obese 
24 weeks 
3 d per 
week 
 
Supervised 
Weight machines and body weight 
RT low intensity – 1-8 weeks: 2 sets, 9-24 
weeks: 3 sets, 45-50% 1RM 
RT mod intensity – 1-8 weeks: 2 sets, 9-24 
weeks: 3 sets, 60-65% 1RM 
RT high intensity – 1-8 weeks: 2 sets, 9-24 
weeks: 3 sets, 80-85% 1RM 
 
Baseline 
and 24 
weeks 
Follow up 
at 48 
weeks 
 
Fenkci et al. 
2006 
Turkey 
RT = 44 ± 10.2 yrs 
AT = 41.7 ± 6.9 yrs  
CON = 43.8 ± 7.4 yrs 
Female 
Sedentary obese 
12 weeks 
3 d per 
week 
Supervision not reported 
Weight machines 
1 week: 1 set of 10 reps of 40-60% 1RM 
2 weeks: 2 sets of 10 reps of 40-60% 1RM 
3 weeks: 3 sets of 10 reps of 40-60% 1RM 
4-12 weeks: 3 sets of 75-80% 1RM 
Baseline 
and 12 
weeks 
 
Figueroa et 
al. 2012 
 
Figueroa et 
al. 2013 
 
Figueroa et 
al. 2013 
USA 
Not reported. 
 
RT with WBV = 56 ± 3 yrs 
CON = 56 ± 3 yrs 
 
RT with WBV = 55.5 ± 0.7 
yrs 
CON = 56.4 ± 1 yrs  
Female 
Sedentary obese 
6 weeks  
12 weeks 
3 d per 
week 
Supervised 
Whole body vibration with free weights 
Vibration intensity was progressed by 
increasing the frequency (25–30Hz) and 
amplitude (1–2mm). The duration of the 
sets and rest periods was progressively 
increased (30–60 s) and decreased (60–30 
s), respectively.  
Baseline 
and 6 
weeks 
 
Franklin et al. 
2015 
USA 
RT = 30.3 ± 5.4 yrs 
CON = 30.8 ± 9.0 yrs 
Female 
Sedentary obese 
8 weeks 
2 d per 
week 
Supervised 
Free weights and machines 
2-3 sets of 10 reps at 80–90% 10RM 
Baseline 
and 8 
weeks 
Supported by the National 
Heart, Lung, and Blood Institute 
grants lK23HL85614, 
RO1HL095701, and HL095701-
01A2S, and the University of 
Illinois at Chicago, Centre for 
Clinical and Translational 
Science, award UL1RR029879 
from the National Centre for 
Research Resources. 
Garcia-Lopez 
et al. 2007 
Finland 
RT = 54.9 ± 1.9 yrs 
AT = 53.6 ± 2.4 yrs  
CON = 53.3 ± 2.5 yrs 
Male 
Healthy sedentary 
21 weeks 
2 d per 
week 
Supervised 
Weight machines 
1-7 weeks: 2-4 sets of 8-15 reps at 40–70% 
1RM 
8–14 weeks: 2-5 sets of 5-12 reps at 60–
80% 1RM 
15-21 weeks:3-5 sets of 5-10 reps at 60–
85% 1RM  
Baseline, 
10.5 (not 
control 
group) and 
21 weeks 
Funded, in part, by a grant from 
the Ministry of Education, 
Finland. 
Gater et al. 
1992 
USA 
Physically active 10 weeks Not reported Baseline 
and 10 
weeks 
Grant from Ross Laboratories, 
the Achievement Reward for 
College Scientists Foundation, 
and National Heart, Lung and 
Blood Institute Research 
Services Award HL-07249. 
Gelecek et 
al. 2012 
Turkey 
RT = 54.3 ± 5.3 yrs 
CON = 51.8 ± 3.7 yrs 
Female 
Post-menopausal 
12 weeks 
3 d per 
week 
 
Supervised 
Free weights and machines 
2 sets of 8-12 reps at 60% 1RM  
Baseline 
and 12 
weeks 
Funded by the Department of 
Scientific Research Projects of 
Dokuz Eylül University. 
Gettman et 
al. 1978 
USA 
Physically active 20 weeks 
3 d per 
week 
 
Supervision not reported 
Free weight, weight machines and body 
weight 
1-6 weeks: 10-20 reps per set at 50% 1RM 
7-20 weeks: 15 reps per set at 50% 1RM  
Baseline 
and 20 
weeks 
Supported by the International 
Association of Chiefs of 
Police/Law Enforcement 
Assistance Administration, Grant 
No. 76-NI-99-001 
Gordon et al. 
2006 
UK 
RT = 67 ± 2 yrs  
CON = 67 ± 2 yrs 
Male and female Type 2 
diabetes   
16 weeks 
3 d per 
week 
 
Supervision not reported 
Weight machines 
3 sets of 8 reps at 60-65% 1RM 
Baseline 
and 16 
weeks 
Supported by the Brookdale 
Foundation, USDA ARS 
Cooperative Agreement 58-
1950-9-00 I and NIH GCRC 
grant MOl RR000054. 
Greenwood 
et al. 2015 
USA 
RT = 54.6 ± 10.6 yrs 
AT = 53.9 ± 10.7 yrs 
CON = 49.5 ± 10.6 yrs 
Male and female  
Kidney transplant recipients 
12 weeks 
3 d per 
week 
 
Supervised 
Elastic resistance bands, ankle weights and 
free weights 
1-2 sets of 10 reps at 80% 1RM 
 
Baseline 
and 12 
weeks 
Funded by an NIHR Doctoral 
Research Fellowship. The study 
was hosted in the King’s College 
Hospital NIHR clinical research 
facility. This article presents 
independent research funded by 
the NIHR. 
Gregory et 
al. 2013 
USA 
Total cohort = 20.3 ± 0.3 
yrs 
Female 
Physically active 
8 weeks 
3 d per 
week 
 
Supervised 
Free-weight, machine and body weight 
exercises 
3 sets of 3-12RM  
Baseline, 4 
and 8 
weeks 
Grant from the U.S. Army 
Medical Research and Materiel 
Command Bone Health and 
Military Medical Readiness 
Research Program to BCN. 
Hagberg et 
al. 1989 
USA 
Total cohort = 72 ± 3 yrs 
Male and female 
Healthy sedentary 
26 weeks 
3 d per 
week 
Supervised 
Weight machines 
8-12 reps 
Baseline, 
13 (not 
controls 
and 26 
weeks  
Funded, in part, by a grant from 
the Diabetes Treatment Centres 
of America Foundation. 
Hagerman et 
al. 2000 
UK 
RT = 63.7 ± 5 yrs 
CON = 66.2 ± 6.5 yrs 
Male 
Healthy elderly 
16 weeks 
2 d per 
week 
Supervision not reported 
Free-weight, machine and body weight 
exercises 
1 set of 10 reps at 85-90% 1RM followed by 
3 sets to failure of 6-8 reps at 85-90% 1RM  
Baseline 
and 16 
weeks 
 
Hagstrom et 
al. 2016 
Australia 
RT - 51.2 ± 8.5 yrs 
CON - 52.7 ± 9.4 yrs 
Female 
Breast cancer 
16 weeks 
3 d per 
week 
Supervised 
Free weight and weight machines 
3 sets of 8-10 reps at 8RM 
Baseline 
and 16 
weeks 
Supported by a grant from 
Western Sydney University, 
Australia. 
Hallsworth et 
al. 2011  
Jakovljevic et 
al. Finland 
RT = 52 ± 13.3 yrs 
CON = 62 ± 7.4 yrs  
RT = 49 ± 13 yrs 
CON= 62 ± 7 yrs 
Male and female 
Non-alcoholic fatty liver 
disease 
8 weeks 
3 d per 
week 
Supervision biweekly 
Free weights and weight machine 
2 sets at 50% 1RM  
Baseline 
and 8 
weeks 
 
Hautala et al. 
2006 
Canada 
RT = 42 ± 1 yrs  
CON = 41 ± 1 yrs 
Male and female 
Healthy sedentary 
2 weeks 
5 d per 
week 
Supervised 
1 set of 8-12 reps 
Baseline 
and 2 
weeks 
Funding from the EU Seventh 
Framework Programme 
(FP7/2007-2013) under grant 
agreement no Health-F2-2009-
241762, for the project FLIP; the 
MRC; the UK NIHR Biomedical 
Research Centre on Ageing and 
Age-Related Diseases and 
Diabetes UK. 
Haykowsky 
et al. 2000 
Canada 
RT = 68 ± 3 yrs 
CON = 68 ± 4 yrs 
Male 
Healthy elderly 
16 weeks  
3 d per 
week 
Supervision not reported 
Free weights and weight machine 
3-10 reps at 60-80% 1RM 
Baseline, 4, 
8, 12 and 
16 weeks 
Grants from the Ministry of 
Education (Helsinki, Finland) 
and the Medical Council of the 
Academy of Finland (Helsinki, 
Finland). 
Haykowsky 
et al. 2005 
Iran 
RT = 70 ± 4 yrs 
AT = 66 ± 3 yrs 
Combined = 68 ± 6 yrs 
CON = 67 ± 4 yrs 
Female 
Healthy elderly 
12 weeks 
3 d per 
week 
Supervised 
2 sets of 10 reps at 50% 1RM 
Baseline 
and 12 
weeks 
 
Hedayati et 
al. 2012 
USA 
RT 40% 1RM = 23.2 ± 1 yrs  
RT 80% 1RM = 21.9 ± 1.5 
yrs 
CON = 20.8 ± 1 yrs 
4 weeks  
4 d per 
week 
Supervision not reported 
Free weights and machines  
3 sets of 8-11 reps 
Baseline 
and 4 
weeks 
 
Female 
Physically active 
Heffernan et 
al. 2013 
USA 
RT = 60 ± 2 yrs 
CON = 63 ± 2 yrs 
Sex not reported. 
Pre-hypertensive and newly 
diagnosed/never-treated 
hypertensive 
12 weeks 
3 d per 
week 
Supervised 
Weight machines 
2 sets of 12-15 reps at 40% 1RM for upper 
body and 60% 1RM for lower body  
Baseline 
and 12 
weeks 
 
Hendrickson 
et al. 2010 
USA 
RT = 21 ± 0.5 yrs 
AT = 21 ± 0.4 yrs 
Combined = 20 ± 0.4 yrs 
CON = 20 ± 0.5 yrs 
Female 
Physically active 
12 weeks 
3 d per 
week 
Supervised 
Free weights, machine and body weight 
exercises 
3–6 weeks - ‘‘light’’ days at 12RM, 
‘‘moderate’’ days at 8–10RM, and ‘‘heavy’’ 
days at 6–8RM loads.  
8–11 weeks - ‘‘light’’ days at 12RM, 
‘‘moderate’’ days at 6–8RM, and ‘‘heavy’’ 
days at 3–5RM  
Baseline 
and 12 
weeks 
 
Hiatt et al. 
1994 
Hiatt et al. 
1996 
Finland 
RT = 67 ± 6 yrs 
AT = 67 ± 7 yrs 
CON = 67 ± 5 yrs 
Male 
Peripheral artery disease 
12 weeks 
4 d per 
week 
3 d per 
week 
Supervised 
Cuff weight secured to the leg 
3 sets or 6RM 
Baseline 
and 12 
weeks 
Funded, in part, by a grant from 
the Medical Research and 
Material Command Bone Health 
Research Program to BCN. 
Hoff et al. 
2007 
Norway 
RT = 62.8 ± 1.4 yrs 
CON = 60.6 ± 3.0 yrs 
Male and female 
Chronic obstructive 
pulmonary disease 
8 weeks 
3 d per 
week 
Supervision not reported 
4 sets of 5 reps at 85-90% 1RM  
Baseline 
and 8 
weeks 
Grant H133G90114 from the 
National Institute on Disability 
and Rehabilitation Research. Dr 
Hiatt is the recipient of a 
National Institutes of Health 
Academic Award in Vascular 
Disease. 
Holviala et al. 
2012 
Belgium 
RT = 56.5 ± 7.6 yrs 
AT = 55.5 ± 8.7 yrs   
Combined = 56.9 ± 7.5 yrs 
CON = 56.7 ± 7.5 yrs 
Male 
Healthy sedentary 
21 weeks 
2 d per 
week 
Supervised 
Weight machines 
1-7 weeks - 40–60% of 1RM 
8-14 weeks - 60–80% of 1RM 
15-21 weeks - 70–85% of the 1RM 
Baseline 
and 21 
weeks 
 
Hoof et al. 
1996 
Canada 
Age not reported. 
Male 
Healthy sedentary 
16 weeks 
3 d per 
week 
Supervised 
Weight machines 
1-4 weeks – 3 sets of 12 reps at 70%1RM 
5-16 weeks - 3 sets of 10 reps at 70% 1RM 
followed by 4 reps at 90% 1RM  
Baseline 
and 16 
weeks 
Funded, in part, by the 
Norwegian Research Council by 
providing a Professor II position 
for Dr Richardson, grant HL-
17731 from the National Heart, 
Lung, and Blood Institute and 
Tobacco Related Disease 
Research Program grant 
#15RT-0100. 
Horne et al. 
1996 
Finland 
Total cohort = 22.3 ± 3.3 
yrs 
Male and female  
Physically active 
12 weeks 
3 d per 
week 
Supervision not reported 
Machines and free weights 
Baseline, 6 
and 12 
weeks 
Grants from the Belgian Ministry 
of Defence. 
Hu et al. 
2009 
USA 
RT = 32.2 ± 7.2 yrs 
CON = 31 ± 7.5 yrs 
Males 
Healthy sedentary 
10 weeks 
2-3 d per 
week 
Supervised Baseline 
and 10 
weeks 
 
Huffman et 
al. 2014 
Norway 
Age not reported. 
Male and female 
Metabolic risk factors 
24 weeks 
3 d per 
week 
Supervised 
Weight machines 
3 sets of 8-12 reps 
 
Baseline 
and 24 
weeks 
Grants from the National 
Technology Agency of Finland, 
the Ministry of Education of 
Finland, Juho Vainio Foundation 
and partially funded by the 
National Science Foundation of 
Guangdong Province 
(815100760100004), China. 
Husby et al. 
2009 
Husby et al. 
2010 
USA 
RT = 58 ± 5 yrs 
CON = 56 ± 8 yrs 
Male and female 
Total hip arthroplasty 
4 weeks 
post-
operative 
5 d per 
week 
Supervised 
Weight machines 
4 sets of 5 reps at 85% 1RM 
Pre-
operative, 1 
week post-
operative, 5 
week 
Follow up 
at 24 and 
52 weeks  
Supported by the National 
Heart, Lung, and Blood Institute, 
National Institute on Aging and 
National Institute of Arthritis and 
Musculoskeletal and Skin 
Diseases. 
Irving et al. 
2015 
Denmark 
Young: 
RT = 25 ± 1 yrs 
AT = 25 ± 1 yrs 
CON = 26 ± 1 yrs 
Combined = 26 ± 1 yrs 
Old: 
RT = 70 ± 1 yrs  
AT = 70 ± 1 yrs 
CON = 71 ± 2 yrs 
Combined = 71 ± 2 yrs 
Male and female 
Healthy sedentary 
8 weeks 
4 d per 
week 
Supervised 
4 sets of 8–10 reps  
Baseline 
and 8 
weeks 
Supported by National Institute 
of Health grant R01-AG09531, 
RO1-DK41973, National Centre 
for Advancing Translational 
Science grants UL1-RR024150 
and KL2-RR024151, CTSA 
Grant Number UL1- TR000135 
from the National Centre for 
Advancing Translational 
Sciences a component of the 
National Institutes of Health. 
Jay et al. 
2011 
Finland 
RT = 44 ± 8 yrs 
CON = 43 ± 10 yrs 
Male and female 
Healthy sedentary 
8 weeks 
3 d per 
week 
Supervised 
Kettlebells 
Baseline 
and 8 
weeks 
Funded by The National 
Research Centre for the 
Working Environment. 
Kaikkonen et 
al. 2000 
Brazil 
RT = 42.5 ± 7 yrs 
AT = 41.6 ± 6 yrs             
CON = 41.9 ± 7 yrs 
Male and female  
Healthy sedentary 
12 weeks 
3 d per 
week 
No supervision provided 
Weight machines 
3 circuits of 10 stations 
 
Baseline 
and 12 
weeks 
 
Kanegusuku 
et al. 2011 
Finland 
RT = 63 ± 1 yrs 
Power Training = 65 ± 1 yrs 
CON = 63 ± 1 yrs 
Male 
Healthy elderly 
16 weeks 
2 d per 
week 
Supervision not reported 
Weight machines 
RT: 2 sets, 10 reps at 70% to 4 sets, 4-6 
reps, 85-90% 
PT: 3 sets, 7 reps, 30% to 4 sets, 4-6 reps, 
45-50% 
Baseline 
and 16 
weeks 
Supported by FAPESP 
(#07/56653-1 and #07/00788-6), 
CNPq (#471600/2008-3), 
CAPES, and Head of the 
Psychopharmacology Incentive 
Fund Association. 
Karavirta et 
al. 2009 
Karavirta et 
al. 2011 
Finland 
RT = 56 ± 6 yrs 
AT = 54 ± 8 yrs 
Combined = 56 ± 7 yrs 
CON = 54 ± 8 yrs 
Male 
Healthy sedentary 
21 weeks  
2 d per 
week 
Supervised 
Weight machines and body weight  
1-7 weeks: 3 sets of 15-30 reps at 40–60% 
1RM 
8-14 weeks: 2-4 sets of 6-12 reps at 60–
80% 1RM 
15-21 weeks: 2-4 sets of 5-8 reps at 70–
85% 1RM 
Baseline, 
10.5 and 21 
weeks 
Partially supported by grants 
from the Ministry of Education, 
Finland, Central Finland Health 
Care District, Jyväskylä, Finland, 
and Polar Electro Oy. 
Partly supported by the Ministry 
of Education, Finland and the 
Juho Vainio Foundation, 
Finland. 
Karavirta et 
al. 2013 
Japan 
RT = 52 ± 8 yrs 
AT = 52 ± 7 yrs 
Combined = 49 ± 6 yrs 
CON = 52 ± 8 yrs 
Female 
Healthy sedentary 
21 weeks 
2 d per 
week 
Supervised 
Weight machines and body weight  
1-7 weeks: 3 sets of 12-20 reps at 40–60% 
1RM 
8-14 weeks: 2-4 sets of 5-12 reps at 60–
80% 1RM 
15-21 weeks: 2-4 sets of 5-8 reps at 70–
85% 1RM 
Baseline, 
10.5 and 21 
weeks 
Partly supported by the grants 
from the Ministry of Education 
and Culture, Central Finland 
Health Care District, Juho Vainio 
Foundation, Yrjo Jahnsson 
Foundation, the University of 
Jyväskylä, G. Harold and Leila 
Y. Mathers Charitable 
Foundation, James S. 
McDonnell Foundation, the 
National Institutes of Health-
sponsored Research Resource 
for Complex Physiologic 
Signals, and the National 
Institute on Aging. 
Karelis et al. 
2015 
Canada 
RT - 45. 3± 14 yrs 
CON - 39.4 ± 8 yrs 
Male and female 
Kidney transplant patients 
16 weeks 
3 d per 
week 
Supervised for 1 session a week 
Free weight, weight machines, body weight 
and elastic resistance 
3 sets of 10 reps at 80% 1RM 
Baseline 
and 16 
weeks 
 
Supported by funds from 
investigator-sponsored research 
by AstellasPharma Canada, Inc 
(SG112). RRL is supported by 
the Fonds de Recherche du 
Québec - Santé and holds the J-
A De Sève research chair. MJH 
is supported by the Canadian 
Institutes of Health Research 
and Canadian National 
Transplant Research Program 
and holds the Shire chair in 
nephrology and renal 
transplantation and regeneration 
at the Université de Montréal. 
Kawano et 
al. 2006 
Canada 
RT = 20 ± 1 yrs    
Combined = 21 ± 1 yrs 
CON = 22 ± 1 yrs 
Male 
Healthy sedentary 
20 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3 sets at 50%1 RM 
Baseline, 8 
and 12 
weeks 
Follow up 
at 24 and 
32 weeks 
Grants from the Ministry of 
Health, Labour and Welfare 
(H18-J-W-002), Japan Society 
for the Promotion of Science 
(17300226), and the National 
Institutes of Health in the US 
(AG20966). 
Kell & 
Asmundson 
2009 UK 
RT = 40.1 ± 8.7 yrs 
AT = 36.7 ± 8.9 yrs 
CON = 35.3 ± 7.3 yrs 
Male and female 
Chronic lumbar pain 
16 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
4 sets of 10 reps at 53–72% 1RM 
Baseline, 8 
(not 
controls) 
and 16 
weeks 
Support from the Saskatchewan 
Health Research Foundation 
(New Investigator Grant) and the 
University of Alberta, Augustana 
Campus (travel grant). 
Kemi et al. 
2011 
Iran 
RT = 20.8 ± 2.4 yrs 
CON = 23 ± 2.9 yrs 
Female 
Healthy sedentary 
8 weeks 
3 d per 
week 
Supervised 
Free weights 
5 sets of 5 reps at 85% 1RM 
Baseline 
and 8 
weeks 
 
Kemmler et 
al. 2016 
Germany 
HIT = 42.9 ± 5.4 yrs 
CON = 42.5 ± 5.6 yrs 
Male 
Healthy sedentary 
22 weeks 
2-3 d per 
week 
Supervised 
Weight machines 
Single set to failure of 6-8 reps 
Baseline 
and 22 
weeks 
The authors are grateful for the 
support of the Staedtler-Stiftung 
(Nürnberg, Germany), Kieser 
Training (Erlangen, Germany), 
Post SV Nürnberg (Nürnberg, 
Germany), and Protein4you 
(Saarlouis, Germany).  
Khorvash et 
al. 2012 
USA 
Total cohort = 25.1 ± 3.2 
yrs 
Male 
Depression and anxiety 
10 weeks 
2 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
Baseline 
and 10 
weeks 
 
Kim et al. 
2011 
Switzerland 
Traditional RT = 20.8 ± 0.8 
yrs 
Super slow RT = 19.5 ± 0.3 
yrs 
CON = 21.5 ± 0.8 yrs 
Female 
Healthy sedentary 
4 weeks  Supervision not reported 
Weight machines 
Traditional RT: 3 sets of 8 reps at 80% 1RM 
Super slow RT: 1 set to fatigue at 50% 1RM 
Baseline 
and 4 
weeks 
 
Kriemler et 
al. 2013 
Korea 
RT = 19 yrs 
AT = 23.8 yrs  
CON Swiss = 20.3 yrs 
CON German = 19.5 yrs 
Male and female 
Cystic fibrosis 
24 weeks 
3 d per 
week 
Supervision for 1 session a week 
1 set of 6-9 reps at 10RM 
Baseline, 
12 and 24 
weeks  
Follow up 
at 52 and 
104 weeks 
Grant from the Swiss CF 
Foundation and the German 
Mukoviszidose e.V. 
Ku et al. 
2010 
Korea 
RT = 55.7 ± 6.2 yrs 
AT = 55.7 ± 7 yrs 
CON = 57.8 ± 8.1 yrs 
Female 
Type 2 diabetes 
12 weeks 
4 d per 
week 
Supervised 
Elastic resistance bands  
3 sets of 15-20 reps 
Baseline 
and 12 
weeks 
 
Kwon et al. 
2010 
Korea 
RT = 55.7 ± 6.2 yrs 
CON = 57 ± 8 yrs 
Female 
Type 2 diabetes 
12 weeks 
3 d per 
week 
Supervision not reported 
Elastic resistance bands  
3 sets of 10-15 reps 
Baseline 
and 12 
weeks 
Supported by Korean Diabetes 
Clinical Research Institution. 
Kwon et al. 
2011 
Canada 
RT = 56.3 ± 6.1 yrs 
AT = 55.5 ± 8.6 yrs 
CON = 58.9 ± 5.7 yrs 
Female 
Type 2 diabetes 
12 weeks 
3 d per 
week 
Supervision not reported 
Elastic resistance bands  
3 sets of 10-15 reps 
Baseline 
and 12 
weeks 
 
Larose et al. 
2010 
USA 
RT = 54.7 ± 7.5 yrs 
AT = 53.9 ± 6.6 yrs   
Combined = 53.5 ± 7.3 yrs 
CON = 54.8 ± 7.2 yrs 
Male and female 
Type 2 diabetes  
Run in of 4 
weeks 
followed by 
22 weeks 
intervention
. 2-3 d per 
week 
Supervised 
Biweekly supervision after week 4 
Weight machines  
4 week run-in phase: 1-2 sets of 10 reps 
5-22 weeks: 3 sets of 8 reps  
Baseline 
and 22 
weeks 
Grants from the Canadian 
Institutes of Health Research 
(grant MCT-44155), Canadian 
Diabetes Association (The Lillian 
Hollefriend Grant), and the 
Interfaculty Grant program of the 
University of Ottawa. 
LeMura et al. 
2000 
Australia 
RT = 20 ± 1 yrs 
AT = 21 ± 2 yrs 
Cross training = 19 ± 2 yrs  
CON = 20 ± 1 yrs 
Female 
Healthy sedentary 
16 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
1-2 weeks: 1 set of 8-10 reps at 60-70% 
1RM 
3-14 weeks: 3 sets of 8-10 reps at 60-70% 
1RM 
Baseline, 8 
and 16 
weeks 
Follow up  
at 20 
weeks 
 
Levinger et 
al. 2007 
Levinger et 
al. 2008 
Levinger et 
al. 2009 
Brazil 
LoMFC = 48.5 ± 7.7 yrs 
LoMFT = 50.6 ± 5.1 yrs 
HiMFC = 52.3 ± 5.8 yrs 
HiMFT = 51.6  ± 7.1 yrs 
 
LoMFC = 48.9 ± 7.4 yrs 
LoMFT = 50.3 ± 4.1 yrs 
HiMFC = 51.9 ± 5.8 yrs 
HiMFT = 51  ± 7 yrs 
 
LoMFC = 48.5 ± 7.7 yrs 
LoMFT = 50.6 ± 5.1 yrs 
HiMFC = 52.3 ± 5.8 yrs 
HiMFT = 51.6  ± 7.1 yrs 
Male and female Metabolic 
risk factors 
10 weeks 
3 d per 
week 
Supervised 
Weight machines 
Week 1: 2 sets of 15–20 reps at 40–50% 
1RM 
Week 2: 3 sets of 15–20 reps at 50–60% 
1RM 
3-6 weeks: 3 sets of 12–15 reps at 60–75% 
1RM 
7-10 weeks: 3 sets 8 –12 reps at 75–85% 
1RM 
Baseline 
and 10 
weeks 
 
Libardi et al. 
2011 
Libardi et al. 
2012 
Taiwan 
RT = 48.6 ± 5 yrs 
Concurrent = 48.5 ± 5.3 yrs 
CON = 49.1 ± 5.5 yrs  
Male 
Healthy sedentary 
 
16 weeks 
3 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
3 sets at 8-10RM 
Baseline 
and 16 
weeks 
Supported by the National 
Council of Technological and 
Scientific Development, Brazil. 
Supported by the National 
Counsel of Technological and 
Scientific Development, Brazil. 
RT = 49.3 ± 4.8 yrs 
AT = 49.3 ± 5.4 yrs 
Concurrent = 48.5 ± 5.4 yrs 
CON = 49.1 ± 5.9 yrs 
Male 
Healthy sedentary 
Lo et al. 
2011 
Australia 
RT = 20.2 ± 1.4 yrs 
AT = 20 ± 0.7 yrs 
CON = 21.1 ± 1.7 yrs 
Male 
Healthy sedentary  
24 weeks 
3 d per 
week 
Supervised 
Weight machines 
1-8 weeks: 1 set at 15RM 
9-16 weeks: 1 set of 10 reps at 75% 1RM 
17-24 weeks: 2 sets of 4 reps at 90% 1RM 
Baseline 
and 24 
weeks 
Follow- up 
at 48 
weeks 
Supported by the National 
Science Council, 95-2413-H-
006-010, Taiwan, ROC. 
Lovell et al. 
2009 
Lovell et al. 
2012 
USA 
RT = 74.1 ± 2.7 yrs 
CON = 73.5 ± 3.3 yrs 
 
RT = 74.1 ± 2.7 yrs 
AT = 75.2 ± 3.0 yrs  
CON = 73.5 ± 3.3 yrs 
Male 
Healthy elderly 
16 weeks 
3 d per 
week 
Supervised 
Weight machine 
3 sets of 6-10 reps at 50-90%1RM 
Baseline, 4, 
8, 12, and 
16 weeks 
 
Madden et 
al. 2006 
Iran 
RT = 69.8 ± 1.5 yrs 
AT = 70 ± 2.6 yrs 
CON = 71.8 ± 1.2 yrs 
Female 
Healthy elderly 
24 weeks 
5 d per 
week 
Supervised 
Free weights 
3 sets of 8-12 reps at 85% 1RM 
Baseline 
and 24 
weeks 
Supported by the AHA 
Washington Affiliate Grant-in-
aid, the Medical research 
service of the department of 
veterans affairs 
Mahdirejei et 
al. 2014 
Australia 
RT = 47.6 ± 7.7 yrs 
CON = 49.6 ± 8.1 yrs 
Male 
Type 2 diabetes 
8 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3 sets of 8-15 reps at 50-80% 1RM 
Baseline 
and 8 
weeks 
Supported by Islamic Azad 
University Sari Branch, Sari, 
Iran. 
Maiorana et 
al. 1997 
Australia 
RT = 61.2 ± 8.4 yrs 
CON = 59 ± 8.7 yrs 
Male 
Coronary bypass graft 
10 weeks Supervised 
Free weights, weight machines and body 
weight 
1-3 sets of 10-15 reps at 40-60% MVC 
Baseline 
and 10 
weeks 
 
Maiorana et 
al. 2011 
USA 
RT = 58.8 ± 3.5 yrs 
AT = 61.3 ± 2.8 yrs 
CON = 64.4 ± 2.4 yrs 
Male and female 
Stable chronic heart failure 
12 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
1-6 weeks: 3 sets of 60 secs at 50-60% 
1RM 
7-12 weeks: 3 sets of 60 secs at 60-70% 
1RM 
Baseline, 6 
and 12 
weeks 
Supported by the National Heart 
Foundation (Australia), the 
Dutch Heart Foundation (E. 
Dekker, stipend) and the 
Australian Research Council. 
Malin et al. 
2013 
USA 
Normal body fat = 21.9 ± 
0.8 yrs 
High body fat = 21.0 ± 0.8 
yrs 
CON = 20.9 ± 0.6 yrs 
7 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3 sets of 10-12 reps at 60% 1RM 
Baseline 
and 7 
weeks 
Funded by the Wayne State 
College Foundation. 
Female 
Healthy sedentary 
Manning et 
al. 1991 
USA 
RT= 35.4 ± 2.6 yrs 
CON = 40.3 ± 5.5 yrs 
Female 
Sedentary obese 
12 weeks 
3 d per 
week 
Supervision not reported 
Free weights and weight machines 
2-3 sets of 6-8 reps at 60-70% 1RM 
Baseline, 4, 
8 and 12 
weeks 
Supported, in part, by grant from 
the Valley Hospital and the 
William Paterson College of 
New Jersey. 
Marcinik et 
al. 1991 
USA 
RT= 29 ± 4 yrs 
CON = 30 ± 4 yrs 
Male 
Healthy sedentary 
12 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3 sets at 8-20RM 
Baseline 
and 12 
weeks 
 
Marcus et al. 
2009 
Portugal 
RT Eccentric = 56.3 ± 6.4 
yrs 
CON = 53.2 ± 6.5 yrs 
Females  
Impaired glucose tolerance 
12 weeks 
3 d per 
week 
Supervised 
Weight machine 
Baseline 
and 12 
weeks 
Supported by the Utah Building 
Interdisciplinary Research 
Careers in Women's Health 
Program (NIH grant 
5K12HD043449-04). 
Martins et al. 
2010 
Martins et al. 
2010 
USA 
Total cohort = 76 ± 8 yrs  
Male and female 
Healthy sedentary 
 
RT= 73.2 ± 6.5 yrs 
AT = 76.2 ± 7.4 yrs 
CON = 81.2 ± 7.9 yrs  
Males and females 
16 weeks 
3 d per 
week 
Supervised 
Elastic resistance bands 
1-2 weeks: 1 set of 8 reps 
3-4 weeks: 1 set of 12 reps 
5-6 weeks: 2 sets of 8 reps 
7-8 weeks: 2 sets of 10 reps 
9-10 weeks: 2 sets of 12 reps 
11-12 weeks: 2 sets of 15 reps 
13-14 weeks: 3 sets of 12 reps 
15-16 weeks: 3 sets of 15 reps 
Baseline 
and 16 
weeks 
 
Baseline 
and 16 
weeks 
Follow-up 
at 32 
weeks 
Supported by the Portuguese 
Foundation for Science and 
Technology and the Portuguese 
Institute of Sport. 
McDermott et 
al. 2009 
Australia 
RT = 71.7 ± 8.7 yrs 
AT = 71.7 ± 8.7 yrs  
CON = 68.5 ± 11.9 yrs 
Male and female 
Peripheral artery disease 
24 weeks 
3 d per 
week 
Supervised 
Weight machines 
3 sets of 8 reps at 50-80% 1RM 
Baseline 
and 24 
weeks 
Supported by grants R01-
HL073551 from the National 
Heart, Lung, and Blood Institute 
and by RR-00048, National 
Institutes of Health and the 
Intramural Research Program, 
National Institutes on Aging. 
McGuigan et 
al. 2001 
USA 
RT = 70 ± 6 yrs 
CON = 66 ± 6 yrs 
Male and female 
Peripheral artery disease 
24 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
2 sets at 8-15RM 
Baseline, 
12 and 24 
weeks 
Supported by an American 
College of Sports Medicine 
Foundation Research Grant for 
doctoral students. 
Mikesky et 
al. 1994 
Canada 
RT= 69.2 ± 4.0 yrs 
CON = 72.8 ± 5.7 yrs 
Male and female 
Healthy elderly 
12 weeks 
3 d per 
week 
Supervision for 1 session a week 
Body weight and elastic resistance bands  
1-2 weeks: 1 set of 12 reps 
3-4 weeks: 2 sets of 12 reps 
5-12 weeks: 2-3 sets of 12 reps 
Baseline 
and 12 
weeks 
Grant from the Indiana 
University Grant-in-Aid program. 
Millar et al. 
2008 
Japan 
RT = 66 ± 1 yrs  
CON = 67 ± 2 yrs 
Male and female 
Healthy elderly 
8 weeks 
3 d per 
week 
Supervision for 2 sessions a week 
Weight machine 
1 set of 4 reps at 30-40% MVC 
Weekly for 
8 weeks 
Supported by an Ontario 
Graduate Scholarship award 
and a Natural Sciences and 
Engineering Research Council 
of Canada Discovery grant. 
Miura et al. 
2008 
Japan 
RT 1d·week = 69 ± 6.5 yrs 
RT 2d·week = 69.5 ± 7 yrs 
CON = 68.9 ± 7.5 yrs 
Female 
Healthy elderly 
12 weeks 
1 or 2 d per 
week 
 
Supervised 
Free weights and elastic resistance bands 
3–5 sets of 15–20 reps 
Baseline 
and 12 
weeks 
Supported by a Grant-in Aid for 
Scientific Research from the 
Ministry of Education, Science, 
Sports and Culture of Japan 
(15700441). 
Miyachi et al. 
2004 
Norway 
RT = 22 ± 1 yrs 
CON = 22 ± 1 yrs 
Male 
Healthy sedentary 
16 weeks 
3 d per 
week  
Supervised  
Free weights, weight machines and body 
weight 
3 sets of 12 reps at 80% 1RM 
Baseline 
and 16 
weeks 
Follow-up 
at 24 
weeks 
Grants from the National 
Institutes of Health (AG-
020966), Japan Society for 
Promotion of Science 
(13780041 and 14208005) and 
the Meiji Yasuda Life 
Foundation. 
Mosti et al. 
2013 
Norway 
RT = 61.9 ± 5 yrs 
CON = 66.7 ± 7.4 yrs 
Females  
Osteoporosis or osteopenia 
12 weeks 
3 d per 
week 
 
Supervised 
Weight machines 
4 sets of 3–5 reps at 85–90% 1RM 
Baseline 
and 12 
weeks 
Funded by the Liaison 
Committee between the Central 
Norway Regional Health 
Authority and the Norwegian 
University of Science and 
Technology. 
Mosti et al. 
2014 
Brazil 
RT= 22.7 ± 2.2 yrs 
CON = 21.5 ± 2.2 yrs 
Female 
Healthy sedentary 
12 weeks 
3 d per 
week 
Supervised 
Weight machines 
4 sets of 3–5 reps at 85–90% 1RM 
Baseline 
and 12 
weeks 
Corresponding author funded by 
a PhD grant from the Liaison 
Committee between the Central 
Norway Regional Health 
Authority and the Norwegian 
University of Science and 
Technology. 
Mota et al. 
2013 
Iran 
RT = 67.5 ± 7 yrs 
CON = 66.8 ± 5.4 yrs 
Female 
Hypertensive 
16 weeks 
3 d per 
week 
Supervised 
Free weights and weight machines 
1-4 weeks: 3 sets of 10 reps 
5-8 weeks: 3 sets of 12 reps at 60% 1RM 
9-12 weeks: 3 sets of 10 reps at 70% 1RM 
13-16 weeks: 3 sets of8 reps at 80% 1RM 
Baseline, 4, 
8, 12 and 
16 weeks 
 
Nikseresht et 
al. 2014 
Nikseresht et 
al. 2014 
Denmark 
RT non-linear = 40.4 ± 5.2 
yrs 
AT = 39.6 ± 3.7 yrs 
CON = 38.9 ± 4.1 yrs 
                
RT non-linear = 40.4 ± 5.2 
yrs 
AT = 39.6 ± 3.7 yrs 
Lean = 39 ± 5.9 yrs 
CON = 38.9 ± 4.1 yrs 
Male 
Sedentary obese 
12 weeks  
 
12 weeks 
training. 4 
weeks 
detraining 
period 
3 d per 
week 
Supervised 
Free weights and weight machines 
1-4 sets of 2-20 reps at 40-95% 1RM 
Baseline 
and 12 
weeks 
 
Baseline, 
12 weeks 
and follow-
up 
None reported.                                          
Grants from the Ilam University 
of Medical Sciences, Ilam, Iran. 
Nybo et al. 
2010 
Japan 
RT = 36 ± 2 yrs 
Interval running = 37 ± 3 
yrs 
Prolonged running = 31 ± 2 
yrs 
CON = 30 ± 2 yrs 
Male 
Healthy sedentary 
12 weeks 
3 d per 
week 
Supervision not reported 
Free weights and weight machines 
1-4 weeks: 4 sets of 12-16RM 
5-12 weeks: 4 sets at 6-10RM 
Baseline 
and 12 
weeks 
Supported by the Danish 
Ministry of Culture 
(Kulturministeriets Udvalg for 
Idrætsforskning). 
O’Connor et 
al. 2017 
UK 
RT - 54.6 ± 10.6 yrs 
CON - 49.5 ± 10.6 yrs 
Male 
Kidney transplant recipients 
12 weeks 
3 d per 
week 
Supervision for 2 sessions a week 
Free weights, weight machines and body 
weight 
1-3 sets of 10 reps at 80% 1RM 
Baseline 
and 12 
weeks 
Funded by the NIHR. The study 
was hosted in the KCH NIHR 
Clinical Research Facility. This 
paper presents independent 
research funded by the NIHR.  
Okamoto et 
al. 2006 
Japan 
RT Eccentric = 18.9 ± 0.3 
yrs 
RT Concentric 19.1 ± 0.3 
yrs 
CON = 19.9 ± 1.2 yrs 
Female 
Healthy sedentary 
8 weeks 
3 d per 
week 
Supervised 
Free weights 
5 sets of 8-10 reps 80-100% 1RM 
Baseline 
and 8 
weeks  
Follow-up 
(unclear 
duration) 
 
Okamoto et 
al. 2009a 
Japan 
RT Eccentric = 19.6 ± 0.4 
yrs 
RT Concentric = 19.2 ± 0.3 
yrs 
CON = 19.7 ± 0.3 yrs 
Male 
Physically active 
10 weeks 
2 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
5 sets of 8-10 reps at 80% 1RM 
Baseline 
and 10 
weeks 
Partially supported by the 
Ministry of Education, Science, 
Sports and Culture, Grant-in-Aid 
for Young Scientists (B), 
19700539, 2007. 
Okamoto et 
al. 2009b 
Japan 
RT Upper = 20.2 ± 0.4 yrs 
RT Lower = 20 ± 0.5 yrs 
CON =  20.1 ± 0.3 yrs 
Male and female 
Healthy sedentary 
10 weeks 
2 d per 
week 
Supervised 
Free weights and weight machines 
5 sets of 8-10 reps at 80% 1RM  
Baseline 
and 10 
weeks 
 
Okamoto et 
al. 2011 
Japan 
RT = 18.5 ± 0.5 yrs  
CON = 18.6 ± 0.5 yrs 
Male 
Healthy sedentary 
10 weeks 
2 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
5 sets of 10 reps  
Baseline 
and 10 
weeks 
Supported by the Grant-in-Aid 
for Scientists Research from the 
Ministry of Education, Culture, 
Sports, Science and Technology 
of Japan (21700680). 
Okamoto et 
al. 2013 
Norway 
High then low intensity RT 
= 19.1 ± 0.7 yrs 
Low then high intensity RT 
= 19.3 ± 0.7 yrs  
CON = 19.1 ± 0.6 yrs 
Male and female 
Healthy sedentary 
10 weeks 
2 d per 
week 
Supervision not reported 
Free weights and weight machines 
3 sets of 10 reps to concentric failure 
Baseline 
and 10 
weeks 
 
Oldervoll et 
al. 2001 
Brazil 
RT = 42.2 ± 6 yrs 
AT = 42.6 ± 6 yrs  
CON = 43.9 ± 8.8 yrs 
Female 
Musculoskeletal pain 
15 weeks 
2 d per 
week 
Supervision not reported 
2-3 sets of 12-15 reps 
Baseline 
and 15 
weeks 
Grant no. 111222/330 from the 
Norwegian Research Council 
and the University Hospital of 
Trondheim provided financial 
support for the employment of 
one of the instructors. 
Oliveira et al. 
2013 
USA 
RT = 22 ± 3 yrs 
CON = 23 ± 4 yrs 
Male 
Physically active 
8 weeks 
3 d per 
week 
Supervised 
Isokinetic eccentric resistance exercise on 
weight machines 
1-2 weeks: 2 sets of 8 reps 
3-4 weeks: 4 sets of 8 reps 
5-6 weeks: 6 sets of 8 reps 
7-8 weeks: 3 sets of 8 reps 
Baseline 
and 8 
weeks 
Supported by FAPESP and 
CNPq. 
Olson 2006 
Norway 
RT = 38 ± 1 yrs 
CON = 38 ± 2 yrs 
Female 
Sedentary overweight  
52 weeks 
2 d per 
week 
Supervised for the initial 16 weeks 
Free weights and weight machines 
3 sets of 8–10 reps 
Baseline 
and 52 
weeks 
Supported, in part, by the 
National Institutes of Health 
grant #:5R01DK060743-03, 
American Heart Association 
grant #:0410034Z and General 
Clinical Research Centre 
Program, NCRR/NIH #:M01-
RR00400. 
Osteras et al. 
2002 
USA 
RT = 21 ± 1.6 yrs 
CON = 24.4 ± 5 yrs 
Male 
Cross country skiers 
9 weeks Supervision not reported 
Weight machines 
3 sets of 6 reps at 85% 1RM 
 
Baseline 
and 9 
weeks 
 
Panton et al. 
1990 
South Africa 
RT = 72.2 ± 2.5 yrs 
Walk/jog = 71.8 ± 1.9 yrs  
CON = 72.1 ± 3 yrs 
Male and female 
Healthy sedentary 
26 weeks 
3 d per 
week 
Supervised 
Weight machines 
1 set of 8-12 reps 
Baseline 
and 26 
weeks 
 
Parr et al. 
2009 
Spain 
RT Upper = 66 ± 13 yrs 
Conventional Exercise 
Rehab = 57 ± 14 yrs  
CON = 62 ± 10 yrs 
Male and female 
Peripheral artery disease 
6 weeks 
3 d per 
week 
Supervised 
Free weights and weight machines  
15-30 reps 
Baseline 
and 6 
weeks 
 
Perez-
Gomez et al. 
2013 Canada 
RT = 22 ± 1.2 yrs 
ET = 21.8 ± 1 yrs 
CON = 23.3 ± 2.5 yrs 
Male 
Physically active 
10 weeks Supervised 
Free weights and weight machines  
50-90% of 1RM 
Baseline 
and 10 
weeks 
 
Plotnikoff et 
al. 2010 
USA 
RT = 55 ± 12 yrs 
CON = 54 ± 12 yrs 
Male and female Type 2 
diabetes 
16 weeks 
3 d per 
week 
Supervision tapered 
Free weights and weight machines 
Week 1: 2 sets of 10–12 reps at 50–60% 
1RM 
Baseline 
and 16 
weeks 
Funded by the Canadian 
Institutes of Health Research, 
Strategic Initiative in Excellence, 
Innovation and Advancement for 
Week 2: 3 sets of 10-12 reps at 50-60% 
1RM 
3-8 weeks: 3 sets of 10-12 reps, intensity 
progressively increase to 70-80% 1RM 
Week 9: 2 sets of 10–12 reps at 70% 1RM 
10-15 weeks: 3 sets of 8–10 reps at 70–
85% 1RM 
Week 16: 2 sets of 8–10 reps at 80% 1RM. 
the Study of Obesity and 
Healthy Body Weight. 
Poehlman et 
al. 2000 
USA 
RT = 28 ± 3 yrs 
AT = 29 ± 5 yrs 
CON = 28 ± 4 yrs 
Female 
Healthy sedentary 
24 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3 sets of 10 reps 
Baseline 
and 6 week 
Grant from the Department of 
Defence (DE-950226), a post-
doctoral fellowship from the 
American Heart Association,  
Maine/New Hampshire/Vermont 
affiliate, a grant from the Medical 
Research Council of Canada, 
and General Clinical Research 
Centre Grant RR-109. 
Poehlman et 
al. 2002 
USA 
RT = 28 ± 3 yrs 
AT = 28 ± 4 yrs 
CON = 28 ± 4 yrs 
Female 
Healthy sedentary 
24 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3 sets of 10 reps 
Baseline 
and 6 
weeks 
 
Pollock et al. 
1991 
USA 
RT = 72.2 ± 2.5 yrs 
Walk/Jog = 71.8 ± 1.9 yrs       
CON = 72.1 ± 3 yrs 
Male and female 
Healthy elderly 
26 weeks 
3 d per 
week 
Supervision not reported 
Weight machines 
1 set of 10-12 reps 
Baseline 
and 26 
weeks 
 
Prabhakaran 
et al. 1999 
USA 
RT = 28 ± 6 yrs 
CON = 26 ± 6 yrs 
Female 
Healthy sedentary 
14 weeks 
3 d per 
week 
Supervised 
Free weights and weight machines 
85% 1RM 
Baseline 
and 24 
weeks 
Funded by the Yamanaka Fund. 
Rana et al. 
2008 
USA 
RT = 20.6 ± 1.9 yrs 
RT Low Velocity = 19.4 ± 
1.3 yrs 
AT = 22.3 ± 3.9 yrs 
CON = 22.9 ± 2.4  yrs 
Female 
Healthy sedentary 
6 weeks 
week 1 - 2 
sessions  
weeks 2-6 - 
3 days a 
week 
Supervised 
Weight machines 
3 sets at 6-10RM 
Baseline 
and 6 
weeks 
 
Roberts et al. 
2013 
Sweden 
Male 
Sedentary obese 
12 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
1–2 weeks: 2 sets of 12–15 reps 100% 12-
15RM 
3–7 weeks: 3 sets of 8–12 reps at 100% 8–
12RM 
Baseline 
and 12 
weeks 
Supported by the American 
Heart Association (BGIA # 
0765139Y), the National Heart, 
Lung and Blood Institute (P50 
HL105188), the National 
Institute of Diabetes and 
Digestive and Kidney Diseases 
8–12 weeks: 6–8 reps at 100% 6–8RM (DK090406) and the National 
Centre for Advancing 
Translational Sciences through 
UCLA CTSI Grant 
UL1TR000124. 
Rodriguez-
Miguelez et 
al. 2014 
Spain 
RT = 69.1 ± 1.1 yrs 
CON = 70 ± 0.9 yrs 
Male and female 
Healthy elderly 
8 weeks 
2 d per 
week 
Supervision not reported 
Weight machines 
Week 1: 3 sets of 8 reps at 60% 1RM 
Week 2: 3 sets of 10 reps at 60% 1RM 
Week 3: 3 sets of 12 reps at 60% 1RM 
Week 4: 3 sets of 8 reps at 70% 1RM 
Week 5: 3 sets of 10 reps at 70% 1RM 
Week 6: 3 sets of 12 reps at 70% 1RM 
Week 7: 3 sets of 8 reps at 80% 1RM 
Week 8: 3 sets of 10 reps at 80% 1RM 
Baseline 
and 10 
weeks 
Supported by Plan Nacional 
I+D+I DEP2010-17574, Spain. 
Romero-
Areanas et 
al. 2007 
Finland 
High RT Circuit = 62.1 ± 6.3 
yrs 
Traditional RT = 64.8 ± 4.5 
yrs 
CON = 58 ± 5 yrs 
Male and female 
Healthy elderly 
12 weeks 
2 d per 
week 
Supervised 
Weight machines 
High RT Circuit: 1-3 sets 
Traditional RT: 3 sets of 6-12 reps at 50-
100% 6RM 
Baseline 
and 12 
weeks 
Grant 07/UPR20/10 from the 
Consejo Superior de Deportes. 
Sallinen et al. 
2007 
USA 
RT = 57.9 ± 6.6 yrs 
CON = 58.2 ± 6.1 yrs 
Male 
Healthy elderly 
21 weeks 
1-3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3-6 sets of 5-10 reps at 40-80% 1RM 
Baseline, 
21 and 42 
weeks 
 
Sawyer et al. 
2014 
Germany 
Total cohort = 20.6 ± 2 yrs 
Male 
Physically active 
8 weeks 
3 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
3 sets at 8RM 
Baseline 
and 8 
weeks 
 
Schiffer et al. 
2011 
Denmark 
Total cohort = 22.6 ± 1.6 
yrs 
Sex not reported 
Physically active 
12 weeks 
3 d per 
week 
Supervised 
Weight machines 
3 sets of 8-10 reps at 70-80% 1RM 
Baseline 
and 12 
weeks 
Supported by the World Anti-
Doping Agency. 
Schmidt et 
al. 2014 
USA 
RT = 69.1 ± 3.1 yrs 
Football = 68 ± 4 yrs 
CON = 67.4 ± 2.7 yrs 
Male 
Healthy elderly 
52 weeks 
2 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
1-4 weeks: 4 sets of 16-20RM 
5-8 weeks: 4 sets of 12RM 
9-12 weeks: 4 sets of 10RM 
13-52 weeks: 4 sets of 8RM 
Baseline, 
12 and 52 
weeks 
Supported by Nordea-fonden, 
FIFA Medical Assessment and 
Research Centre, Preben and 
Anna Simondsen fonden, and 
The Danish Ministry of Culture. 
Schmitz et al. 
2002 
USA 
RT =41 ± 6 yrs 
CON = 42 ± 6 yrs 
Female 
Healthy sedentary 
15 weeks 
2 d per 
week 
Supervised 
Free weights and weight machines 
3 sets of 8-10 reps 
Baseline 
and 15 
weeks 
Supported by a Minnesota 
Obesity Centre Pilot and 
Feasibility Grant, NIH Grant 
DK50456 from the National 
Follow up 
at 39 
weeks 
Institute of Diabetes and 
Digestive and Kidney Diseases, 
University of Minnesota General 
Clinical Research Centre Grant 
M01- R00400, Tickle Family 
Fund for Breast Cancer 
Research, and Public Health 
Service Cancer Centre Support 
Grant P30 CA77398. 
Schmitz et al. 
2005 
Canada 
RT = 53.3 ± 8.7 yrs  
CON = 52.8 ± 7.6 yrs 
Female 
Breast cancer 
26 weeks 
2 d per 
week 
Supervised for initial 13 weeks 
Free weights and weight machines 
3 sets 
Baseline, 
24 and 52 
weeks 
S.G. Komen Foundation grant 
BCTR0100442 and NIH grants 
M01-RR00400 and T32 
CA09607-15. 
Segal et al. 
2009 
Iran 
RT = 66.4 ± 7.6 yrs 
AT = 66.2 ± 6.8 yrs  
CON = 66.3 ± 7 yrs 
Male  
Prostate cancer 
24 weeks 
3 d per 
week 
Supervised 
Free weights and weight machines 
2 sets of 8-12 reps at 60-70% 1RM 
Baseline 
and 24 
weeks 
Grant 013232 from the 
Canadian Prostate Cancer 
Research Fund. 
Shamsoddini 
et al. 2015 
South Africa 
RT = 45.9 ± 7.3 yrs 
AT = 39.7 ± 6.3 yrs 
CON = 45.8 ± 7.3 yrs 
Males 
Non-alcoholic fatty liver 
disease 
8 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
1-2 weeks: 2 sets of 10 reps at 50% 1RM 
3-4 weeks: 2 sets of 10 reps at 60% 1RM 
5-6 weeks: 3 sets of 10 reps at 60% 1RM 
7-8 weeks: 3 sets of 10 reps at 70% 1RM 
Baseline 
and 8 
weeks 
Supported by Exercise 
Physiology Research Centre 
and Research Centre for 
Gastroenterology and Liver 
Disease in Baqiyatallah 
University of Medical Sciences, 
Tehran, IR Iran. 
Shaw & 
Shaw 2005 
India 
Age not reported 
Male 
Healthy sedentary 
8 weeks 
3 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
3 sets of 15 reps at 60% 1RM 
Baseline 
and 8 
weeks 
 
Shenoy et al. 
2009 
Canada 
RT = 49.6 ± 5.2 yrs 
AT = 52.2 ± 9.3 yrs 
CON = 58.4 ± 1.8 yrs 
Male and female  
Type 2 diabetes 
16 weeks 
2 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
3 sets of 10 reps 
Baseline 
and 16 
weeks 
Grant from the University Grants 
Commission, New Delhi, India. 
Sigal et al. 
2009 
Finland 
RT = 54.7 ± 7.5 yrs 
AT = 53.9 ± 6.6 yrs 
Combined = 53.5 ± 7.3 yrs 
CON = 54.8 ± 7.2 yrs 
Male and female Type 2 
diabetes 
22 weeks 
3 d per 
week 
Supervised 
Weight machines 
2-3 sets of 7-9 reps 
Baseline, 
12 and 24 
weeks 
Grants from the Canadian 
Institutes of Health Research 
(grant MCT-44155), the 
Canadian Diabetes Association, 
a New Investigator Award from 
the Canadian Institutes of Health 
Research, Career Scientist 
Award from the Ontario Ministry 
of Health and Long Term Care, 
a Postgraduate Scholarship 
from the National Sciences and 
Engineering Research Council, 
a New Investigator Award from 
the Heart and Stroke 
Foundation, Doctoral Research 
Award from the Social Sciences 
and Humanities Research 
Council and an Ontario 
Graduate Scholarship. 
Sillanpaa et 
al. 2012 
Sillanpaa et 
al. 2009 
Sillanpaa et 
al. 2009 
USA 
RT = 54.2 ± 8.1 yrs 
AT = 53.7 ± 8.2 yrs 
Combined = 53.9 ± 8 yrs 
CON = 54.5 ± 9.1 yrs 
Male and female 
Healthy elderly 
 
RT = 54.1 ± 6 yrs 
AT = 52.6 ± 7.9 yrs 
Combined = 56.3 ± 6.8 yrs 
CON = 53.8 ± 7.7 yrs 
Males  
 
RT = 50.8 ± 7.9 yrs 
AT = 51.7 ± 6.9 yrs 
Combined = 48.9 ± 6.8 yrs 
CON = 51.4 ± 7.8 yrs 
Female 
Healthy sedentary 
21 weeks 
Endurance 
and 
strength - 2 
d a week; 
Combined 
4 d a week 
Supervised 
Free weights, weight machines and body 
weight 
3-4 sets 
1-7 weeks: 15-20 reps at 40-60% 1RM 
8-14 weeks: 10-12 reps at 60-80% 1RM 
15-21 weeks: 6-8 reps at 70-80% 1RM 
Baseline 
and 21 
weeks 
Supported, in part, by a grant 
from the Ministry of Education, 
Finland, the Central Finland 
Health Care District, Jyväskylä 
Finland, Juho Vainio 
Foundation, Finland, Sport 
Institute Foundation, Finland 
and Yrjö Jahnsson Foundation, 
Finland. 
Simons & 
Andel 2006 
Canada 
RT = 84.6 ± 4.5 yrs 
Walking = 81.6 ± 3.3 yrs 
CON = 84 ± 3.3 yrs 
Male and female 
Healthy elderly 
16 weeks 
2 d per 
week 
Supervised 
Weight machines 
1 set of 10 reps at 75% 1RM 
Baseline 
and 16 
weeks 
 
Simpson et 
al. 1992 
Korea 
RT = 73 ± 4.8 yrs  
CON = 70 ± 5.7 yrs 
Male and female 
Chronic airflow limitation 
8 weeks 
3 d per 
week 
Supervised 
Free weights and weight machines 
3 sets of 10 reps at 50-85% 1RM 
Baseline 
and 8 
weeks 
Grants from the Medical 
Research Council of Canada, 
the Heart and Stroke Foundation 
of Ontario, and the Ontario 
Thoracic Society. 
Song & 
Sohng 2012 
Brazil 
RT = 52.1 ± 12.4 yrs  
CON = 54.6 ± 10.1 yrs 
Male and female 
Haemodialysis 
12 weeks 
3 d per 
week 
Supervised 
Free weights and elastic resistance bands 
3 sets of 10-15 reps 
Baseline 
and 12 
weeks 
 
Souza et al. 
2013 
UK 
RT = 25.9 ± 6.4 yrs 
Interval Training = 24 ± 7.5 
yrs 
CON = 22.5 ± 3.9 yrs 
8 weeks 
2 d a week 
Supervision not reported 
Weight machines 
1–2 weeks: 3 sets at 12RM 
3–4 weeks: 4 sets at 8–10RM 
Baseline 
and 8 
weeks 
Grants from Fundação de 
Amparo á Pesquisa do Estado 
de São Paulo - 2007/02738-6, 
2010/51428-2, 2009/03143-1 
Male 
Physically active 
5–6 weeks: 5 sets at 6–8RM 
7–8 weeks: 3 sets at 10–12RM 
and Conselho Nacional de 
Desenvolvimento Científi co e 
Tecnológico (CNPq) – 
152658/2011-4, 470207/2008-6 
and 303162/2008-2. 
Stebbings et 
al. 2013 
Belgium 
RT = 19 ± 3 yrs 
CON = 23 ± 2.4 yrs 
Male and female Physically 
active 
8 weeks (4 
weeks of 
detraining) 
3 d per 
week 
Supervision of 2 sessions a week 
Weight machines and body weight 
3 sets of 10 reps at 80% 1RM 
Baseline, 8, 
10 and 12 
weeks 
 
Stegen et al. 
2015 
Norway 
RT = 54.8 ± 7.6 yrs 
AT = 54 ± 6.6 yrs 
CON = 54.6 ± 7.1 yrs 
Combined = 53.6 ± 7.2 yrs 
Male and female 
Type 2 diabetes 
24 weeks 
3 d per 
week 
Supervised 
Biweekly supervision after week 4 
Weight machines 
2-3 sets if 7-9 reps 
Baseline 
and 24 
weeks 
Grants from the Research 
Foundation- Flanders (FWO 
G.0243.11 and G.0352), 
Canadian Institutes of Health 
Research (Grant MCT-44155), 
the Canadian Diabetes 
Association, a Health Senior 
Scholar Award from Alberta 
Innovates-Health Solutions and 
a Research Chair from the 
University of Ottawa. 
Stensvold et 
al. 2010 
Norway 
RT = 50.9 ± 7.6 yrs 
AT = 49.9 ± 10.1 yrs 
Combined = 52.9 ± 10.4 yrs 
CON = 47.3 ± 10.2 yrs 
Male and female 
Metabolic syndrome 
12 weeks 
3 d per 
week 
Supervised  
Week 1: 60% 1RM 
2-13 weeks: 3 sets of 8-12 reps at 80% 
1RM 
Baseline 
and 12 
weeks 
Supported by the Liaison 
Committee between the Central 
Norway Regional Health 
Authority and the Norwegian 
University of Science and 
Technology. 
Stensvold et 
al. 2012 
Norway 
RT = 50.9 ± 7.6 yrs 
AT = 49.9 ± 10.1 yrs 
CON = 47.3 ± 10.2 yrs 
Male and female 
Metabolic syndrome 
13 weeks 
4 d per 
week 
Supervised 
Week 1: 60% 1RM 
2-13 weeks: 3 sets of 8-12 reps at 80% 
1RM 
1 and 12 
weeks 
Grants from Raagholts 
Foundation. 
Storen et al. 
2008 
Austria 
RT = 28.6 ± 10.1 yrs 
CON = 29.7 ± 7 yrs 
Male and female 
Long distance runners 
8 weeks 
3 d per 
week 
Supervised 
Free weights 
4 sets at 4RM 
Baseline 
and 8 
weeks 
 
Strasser et 
al. 2009 
Norway 
RT = 74 ± 5 yrs 
AT = 76 ± 5 yrs 
CON = 74 ± 5 yrs 
Male and female 
Healthy elderly 
24 weeks 
3 d per 
week 
Supervised 
Free weights, weight machines and body 
weight 
3-6 sets (per week) of 10-15 
Baseline 
and 24 
weeks 
 
Sunde et al. 
2010 
Japan 
RT = 29.9 ± 7.2 yrs 
CON = 35.8 ± 11.8 yrs 
Male and female 
Cyclists 
8 weeks 
3 d per 
week 
Supervised 
Weight machines 
4 sets at 4 RM 
Baseline 
and 8 
weeks 
Supported by Telemark 
University College. 
Tanimoto et 
al. 2009 
Turkey 
RT Low intensity = 19.0 ± 
0.2 yrs 
RT High intensity = 19.5 ± 
0.1 yrs 
CON = 19.8 ± 0.2 yrs 
Male 
Physically active 
13 weeks  
2 d per 
week 
Supervision not reported 
RT Low intensity: 3 sets at 55-60% 1RM) 
RT High intensity: 3 sets at 85-90% 1RM 
Baseline 
and 13 
weeks 
 
Thabitha et 
al. 2012 
India 
Chronic obstructive 
pulmonary disease 
3 d per 
week 
Supervised 
Free weights and weight machines 
1-3 sets of 10 reps 
Baseline 
and 
endpoint 
(unknown) 
 
Tsutsumi et 
al. 1997 
USA 
RT high intensity/low 
volume = 67.8 ± 4.9 yrs  
RT low intensity/high 
volume = 68.9 ± 7.5 yrs  
CON = 69.8 ± 4.6 yrs 
Male 
Healthy elderly 
12 weeks 
3 d per 
week 
Supervised 
RT high intensity/low volume: 8-12reps at 
75-85% 1RM 
RT low intensity/high volume: 12-16 reps at 
55-65% 1RM 
Baseline 
and 12 
weeks 
 
Van de Rest 
et al. 2014 
Netherlands 
Placebo: 
RT = 79.2 ± 6.3 yrs 
CON = 81.2 ± 7.4 yrs 
Protein: 
RT = 77.7 ± 8.8 yrs  
CON = 77.9 ± 8.1 yrs 
Male and female 
Healthy elderly 
24 weeks 
2 d per 
week 
Supervised 
Weight machines 
3-4 sets of 8-15 reps at 50-75% 1RM 
Baseline 
and 24 
weeks 
Funded by Top Institute Food 
and Nutrition and co-financed by 
the Dutch Dairy Association 
(NZO) and the European 
Union’s Seventh Framework 
Program under Grant 
Agreement No. 266486. 
Vatani et al. 
2011 
Iran 
Moderate intensity = 20.8 ± 
1.5 yrs  
High intensity = 19.9 ± 0.7 
yrs 
CON = 20.9 ± 1.1 yrs 
Male 
Healthy sedentary 
6 weeks 
3 d per 
week 
Supervision not reported 
Weight machines 
MI- 45-55% 1RM in 3 sets with 10-12 reps 
per set                                                                            
HI - 80-90% 1RM in 3 sets with 4-6 reps per 
set 
Baseline 
and 6 
weeks 
 
Venojarvi et 
al. 2013 
Venojarvi et 
al. 2013 
Finland 
RT = 54 ± 6.1 yrs 
Nordic walking = 55 ± 6.2 
yrs 
CON = 54 ± 7.2 yrs  
 
RT = 54 ± 1.1 yrs 
Nordic walking = 55 ± 1 yrs  
CON = 54 ± 1 yrs 
Male 
Sedentary obese 
13 weeks 
4 d per 
week 
 
12 weeks 
3 d per 
week 
Supervised 
Free weights and weight machines 
5RM 
Baseline 
and 12 
weeks 
Grants from the Research 
Council for Physical Education 
and Sports, the Finnish Ministry 
of Education, and Turku 
University of Applied Sciences 
R&D program. 
 
Grants from the Research 
Council for Physical Education 
and Sports, of the Finnish 
Ministry of Education, Turku 
University of Applied Sciences 
R&D program and the COST 
action CM1001. 
Vincent et al. 
2002 
Vincent et al. 
2003 
Vincent et al. 
2003 
USA 
LEX = 67.6 ± 6.3 yrs 
HEX = 66.6 ± 6.7 yrs 
CON = 71 ± 4.7 yrs  
 
LEX = 67.4 ± 7 yrs 
HEX = 66.5 ± 7 yrs 
CON = 71.1 ± 5 yrs 
 
LEX = 67.6 ± 6 yrs  
HEX = 66.6 ± 7 yrs  
CON = 71.1 ± 5 yrs 
Male and female 
Healthy elderly 
24 weeks 
3 d per 
week 
Supervised 
Weight machines 
LEX – 1 set of 13 reps at 50% 1RM 
HEX – 1 set of 8 reps at 80% 1RM 
 
Supervision not reported 
 
Baseline 
and 24 
weeks 
 
Vincent et al. 
2006 
USA 
Normal weight: 
RT = 68.1 ± 1.5 yrs 
CON = 70.9 ± 1.4 yrs 
Overweight/obese: 
RT = 66.5 ± 1.2 yrs 
CON =  71.2 ± 2.1 yrs 
Male and female 
Sedentary obese 
24 weeks 
3 d per 
week 
Supervision not reported 
Weight machines 
1 set of 8-13 reps at 50-80% 1RM 
Baseline 
and 24 
weeks 
Supported, in part, by Grants 
T32-AT00052 and K30-AT-
00,060 from the National Centre 
for Complementary and 
Alternative Medicine. 
Vona et al. 
2009 
Switzerland 
RT = 57 ± 8 yrs 
AT = 56 ± 6 yrs 
Combined = 55 ± 9 yrs 
CON = 58 ± 7 yrs 
Male and female  
Cardiac rehabilitation 
4 weeks 
4 d per 
week 
Supervision not reported 
Free weights and elastic resistance bands 
4 sets of 10-12 reps at 60% 1RM 
Baseline 
and 4 
weeks 
 
Wanderley et 
al. 2013 
Portugal 
RT = 67.3 ± 4.9 yrs 
AT = 69.9 ± 5.7 yrs 
CON = 67.8 ± 5.5 yrs 
Male and female 
Healthy elderly 
32 weeks 
3 d per 
week 
Supervised 
Weight machines 
2 sets of 12-15 reps at 50-60%1RM 
progressing to 80% 1RM at week 4 
Baseline 
and 32 
weeks 
Supported by the Portuguese 
Foundation for Science and 
Technology (grant numbers, 
PTDC/DES/108780/2008 and 
SFRH/BD/33124/2007). 
Weiser & 
Haber 2007 
Austria 
RT = 76.1 ± 2.9 yrs 
CON = not reported 
Male and female 
Healthy elderly 
12 weeks 
2 d per 
week 
Supervision not reported 
Free weights, weight machines and body 
weight 
1-4 weeks: 1 set of 10-15 reps 
5-8 weeks: 3 sets of 10-15 reps 
9-12 weeks: 4 sets of 10-15 reps 
Baseline 
and 12 
weeks 
 
Wiles et al. 
2010 UK 
18-34 years 
Male 
Physically active 
8 weeks 
3 d per 
week 
Supervision not reported 
Isometric exercise 
75% and 95% peak heart rate 
Baseline, 4 
and 8 
weeks 
 
Yavari et al. 
2012 
Iran 
RT = 51.5 ± 6.3 yrs 
AT = 48.2 ± 9.2 yrs 
Combined = 50.9 ± 9.8 yrs 
CON = 51.5 ± 8.5 yrs 
Sex not reported 
Type 2 diabetes 
52 weeks 
2-3 d per 
week 
Supervised 
Weight machines 
1-4 weeks: 1-2 sets of 8-10 reps at 60% 
1RM 
4-52 weeks: 3 sets of 8-10 reps at 75-80% 
1RM 
Baseline 
and 52 
weeks 
Grant from the Tabriz University 
of Medical Sciences and with a 
co-operation of Endocrinology 
Reasearch Centre of Emam 
Reza haspital (Tabriz University 
of Medical Sciences). 
Yoshizawa et 
al. 2009 
Japan 
RT = 47 ± 2 yrs 
AET = 47 ± 2 yrs  
CON = 49 ± 3 yrs 
Female 
Healthy sedentary 
12 weeks 
2 d per 
week 
Supervision not reported 
Weight machines 
3 sets of 10 reps at 60% 1RM.           
Baseline 
and 12 
weeks 
Supported by a Grant for 
Scientific Research from the 
Ministry of Education, Culture, 
Sports, Science and Technology 
of Japan (18300215, 18650186, 
21970), and Health and Labour 
Sciences Research Grants from 
the Ministry of Health, Labour 
and Welfare, Japan. 
Zambom-
Ferraresi et 
al. 2015 
Spain 
RT = 68 ± 7 yrs 
RT + AT = 68 ± 7 yrs 
CON = 69 ± 5 yrs 
Male 
Chronic obstructive 
pulmonary disease 
6 weeks 
2 d per 
week 
Supervision not reported 
Weight machines 
3-4 sets of 6-12 reps at 50-70% 1RM 
Baseline 
and 6 
weeks 
Support from the Spanish 
Ministry of Education and 
Science (Plan NacionalI + D + i 
2004-2007 Strategic action: 
“Sport and physical education” 
Ref: DEP2007-73220), Health 
Sciences Department of 
Government of Navarre. F and a 
pre-doctoral fellowship from the 
Public University of Navarre. 
Zavanela et 
al. 2012 Brazil 
Age not reported 
Male 
Healthy sedentary 
24 weeks 
3-4 d per 
week 
Supervised 
Free weights and weight machines 
3 sets of 10–12 reps at 10–12RM 
Baseline 
and 24 
weeks 
 
 
Table 3. Populations used in the included studies. 
 Population Number Percent 
Healthy Sedentary men and women 46 25.6 
 Elderly men and women 30 16.7 
 Physically active adults aged 18-35 years 20 11.1 
 Postmenopausal women 5 2.8 
    
Clinical    
Cardiac Pre-hypertensive and newly diagnosed/never-
treated hypertensive 
3 1.7 
 Coronary bypass graft 1 0.6 
 Stable coronary heart failure 1 0.6 
 Cardiac rehabilitation 1 0.6 
Cancer Breast cancer  3 1.7 
 Disseminated germ cell cancer 1 0.6 
 Prostate cancer  1 0.6 
Non-cancer Type 2 diabetes 18 10 
 Sedentary obese/overweight 14 7.8 
 Metabolic risk factors or syndrome 5 2.8 
 Peripheral artery disease  4 2.2 
 Chronic obstructive pulmonary disease 4 2.2 
 Kidney transplant 3 1.7 
 Musculoskeletal (e.g. osteoporosis, osteopenia 
or osteoarthritis 
2 1.1 
 Haemodialysis  2 1.1 
 Non-alcoholic fatty liver disease 2 1.1 
 Polycystic ovary syndrome 1 0.6 
 HIV/AIDS 1 0.6 
 Trapezius myalgia 1 0.6 
 Total hip arthroplasty 1 0.6 
 Chronic lumbar pain 1 0.6 
 Cystic fibrosis 1 0.6 
 Young men with depression/anxiety 1 0.6 
 Impaired glucose tolerance 1 0.6 
 Chronic airflow limitation  1 0.6 
    
Table 4. Risk of bias assessment 
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Table 5. The short- (ST), medium- (MT) and long-term (LT) effects of RET on all outcomes reported in healthy young adults aged 
18-40 years. 
* Indicates statistical significance. † Indicates favouring resistance exercise training. # Indicates favouring control. ST - short term, 
MT – medium term, LT – long term, ̇VO2max – aerobic capacity, HDL-chol – high density lipoprotein cholesterol, LDL-chol – low 
density lipoprotein cholesterol. 
Blood marker 
Number 
of studies 
Number of 
participants 
Mean difference 
[95% CI] 
P values Heterogeneity 
RT CON 
SBP (mmHg) MT 11 150 122 -0.56 [-1.57, 0.44] † 0.27 χ² = 49.4, I² = 80%, P < 0.00001 
DBP (mmHg) MT 11 150 124 -0.81 [-1.59, -0.04] † 0.04* χ² = 41.91, I² = 76%, P < 0.00001 
MAP (mmHg) MT 4 44 41 3.48 [2.09, 4.87] # < 0.00001* χ² = 4.19, I² = 28%, P = 0.24 
RHR (bpm) MT 12 157 130 0.12 [-0.79, 1.03] 0.79 χ² = 163.07, I² = 93%, P < 0.00001 
V̇O2max 
(ml/kg/min) 
ST 3 31 24 2.53 [-0.01, 5.07] † 0.05* χ² = 5.06, I² = 61%, P = 0.08 
MT 11 161 126 0.91 [0.29, 1.53] † 0.004* χ² = 28.23, I² = 65%, P = 0.002 
LT 2 33 39 -1.35 [-4.03, 1.33] # 0.32 χ² = 0.01, I² = 0%, P = 0.91 
Total Cholesterol 
(mg/dL) 
MT 6 63 67 6.23 [2.97, 9.49] # 0.0002* χ² = 83.22, I² = 94%, P < 0.00001 
HDL-chol (mg/dL) MT 6 78 76 1.85 [0.74, 2.97] † 0.001* χ² = 42.3, I² = 88%, P < 0.00001 
LDL-chol (mg/dL) MT 6 78 76 -0.30 [-2.49, 1.88] † 0.78 χ² = 70.26, I² = 93%, P < 0.00001 
Triglycerides 
(mg/dL) 
MT 5 70 65 1.74 [0.04, 3.44] # 0.04* χ² = 9.64, I² = 59%, P = 0.05 
Fasted glucose 
(mg/dL) 
MT 4 40 43 3.12 [2.02, 4.22] # < 0.00001* χ² = 21.93, I² = 86%, P < 0.0001 
Table 6. The short- (ST), medium- (MT) and long-term (LT) effects of RET on all outcomes reported in healthy older adults ≥ 41 
years of age. 
* Indicates statistical significance. † Indicates favouring resistance exercise training. # Indicates favouring control. ST – short term, MT –
medium term, LT – long term, HDL-chol – high density lipoprotein cholesterol, LDL-chol – low density lipoprotein cholesterol, HOMA-IR – 
insulin resistance, CRP – C-reactive protein. 
Blood marker 
Number 
of studies 
Number of 
participants 
Mean difference 
[95% CI] 
P values Heterogeneity 
RT CON 
SBP (mmHg) 
MT 12 180 166 -4.36 [-5.73, -2.99] † < 0.00001* χ² = 41.02, I² = 73%, P < 0.00001 
LT 3 72 57 -1.89 [-7.66, 3.88] † 0.52 χ² = 0.31, I² = 0%, P = 0.86 
DBP (mmHg) 
MT 12 180 166 -1.51 [-2.47, -0.54] † 0.002* χ² = 75.02, I² = 85%, P < 0.00001 
LT 3 72 57 -5.95 [-9.30, -2.61] † 0.0005* χ² = 15.57, I² = 87%, P = 0.0004 
MAP (mmHg) MT 3 32 27 -3.91 [-5.37, -2.45] † < 0.00001* χ² = 2.0, I² = 0%, P = 0.37 
RHR (bpm) 
MT 13 214 186 1.80 [0.84, 2.77] # 0.0003* χ² = 34.42, I² = 65%, P = 0.0006 
LT 3 48 34 0.52 [-1.25, 2.30] # 0.56 χ² = 3.6, I² = 44%, P = 0.17 
V̇O2max 
(ml/kg/min) 
MT 13 220 186 -0.31 [-0.90, 0.27] 0.3 χ² = 29.33, I² = 59%, P = 0.004 
LT 7 125 91 1.30 [0.47, 2.13] † 0.002* χ² = 2.28, I² = 0%, P = 0.002 
Total Cholesterol 
(mg/dL) 
MT 8 109 106 -8.20 [-14.52, -1.89] † 0.01* χ² = 10.4, I² = 33%, P = 0.17 
LT 3 45 28 -19.99 [-36.18, -3.80] † 0.02* χ² = 2.32, I² = 14%, P = 0.31 
HDL-chol (mg/dL) 
MT 11 150 140 11.55 [10.16, 12.94] † < 0.00001* χ² = 368.51, I² = 97%, P < 0.00001 
LT 3 45 28 5.01 [-0.10, 10.13] † 0.05 χ² = 8.16, I² = 75%, P = 0.02 
LDL-chol (mg/dL) 
MT 8 109 108 -1.60 [-6.58, 3.37] † 0.53 χ² = 43.85, I² = 84%, P < 0.00001 
LT 2 30 18 -5.63 [-15.79, 4.53] † 0.28 χ² = 1.14, I² = 12%, P = 0.29 
Triglycerides 
(mg/dL) 
MT 10 151 146 -13.27 [-15.92, -10.61] † < 0.00001* χ² = 112.64, I² = 92%, P < 0.00001 
LT 2 30 18 6.02 [-8.62, 20.66] # 0.42 χ² = 0.27, I² = 0%, P = 0.61 
Fasted insulin 
(µU/ml) 
MT 3 73 73 -1.09 [-1.28, -0.89] † < 0.00001* χ² = 2.1, I² = 5%, P = 0.35 
LT 2 47 48 0.27 [-0.03, 0.57] 0.08 χ² = 0.43, I² = 0%, P = 0.51 
HOMA-IR LT 2 23 18 -0.44 [-1.07, 0.19] † 0.17 χ² = 0.1, I² = 0%, P = 0.75 
Fasted glucose 
(mg/dL) 
MT 7 134 130 -4.82 [-6.26, -3.38] † < 0.00001* χ² = 123.38, I² = 95%, P < 0.00001 
LT 3 56 47 3.06 [2.30, 3.82] # < 0.00001* χ² = 5.45, I² = 63%, P = 0.07 
CRP (mg/L) MT 4 74 69 -0.26 [-0.32, -0.20] † < 0.00001* χ² = 4.71, I² = 36%, P = 0.19 
Table 7. The short- (ST), medium- (MT) and long-term (LT) effects of RET on all outcomes reported in older adults ≥ 41 years old 
with cardiometabolic risk factors. 
* Indicates statistical significance. † Indicates favouring resistance exercise training. # Indicates favouring control. ST – short term, MT –
medium term, LT – long term, HDL-chol – high density lipoprotein cholesterol, LDL-chol – low density lipoprotein cholesterol, HOMA-IR – 
insulin resistance, CRP – C-reactive protein. 
Blood marker 
Number of 
studies 
Number of 
participants 
Mean difference 
[95% CI] 
P values Heterogeneity 
RT CON 
SBP (mmHg) 
ST 2 37 37 -5.19 [-7.55, -2.83] † < 0.0001* χ² = 4.4, I² = 77%, P = 0.04 
MT 17 304 312 -8.80 [-9.90, -7.69] † < 0.00001* χ² = 95.83, I² = 83%, P < 0.00001 
LT 4 101 106 -3.42 [-8.03, 1.19] † 0.15 χ² = 4.69, I² = 36%, P = 0.2 
DBP (mmHg) 
ST 2 37 37 -2.47 [-4.59, -0.35] † 0.02* χ² = 5.45, I² = 82%, P = 0.02 
MT 15 219 230 -2.55 [-3.09, -2.01] † < 0.00001* χ² = 103.88, I² = 87%, P < 0.00001 
LT 3 90 97 -1.99 [-5.15, 1.18] † 0.22 χ² = 2.27, I² = 12%, P = 0.32 
MAP (mmHg) MT 2 22 24 -5.92 [-7.72, -4.13] † < 0.00001* χ² = 0.17, I² = 0%, P = 0.68 
RHR (bpm) 
MT 6 81 89 -0.44 [-1.45, 0.58] † 0.4 χ² = 55.3, I² = 91%, P < 0.00001 
LT 2 26 34 -3.06 [-8.19, 2.06] † 0.24 χ² = 1.55, I² = 36%, P = 0.21 
V̇O2max 
(ml/kg/min) 
ST 3 74 68 3.02 [2.45, 3.59] † < 0.00001* χ² = 1.74, I² = 0%, P = 0.42 
MT 11 178 186 2.38 [1.78, 2.98] † < 0.00001* χ² = 47.0, I² = 79%, P < 0.00001 
Total Cholesterol 
(mg/dL) 
MT 10 125 127 6.65 [3.70, 9.60] # < 0.00001* χ² = 62.61, I² = 86%, P < 0.00001 
LT 2 26 34 -7.16 [-25.94, 11.61] † 0.45 χ² = 0.05, I² = 0%, P = 0.82 
HDL-chol (mg/dL) 
MT 14 243 243 1.86 [0.85, 2.87] † 0.0003* χ² = 26.2, I² = 50%, P = 0.02 
LT 3 90 97 2.03 [-1.81, 5.87] † 0.3 χ² = 0.0, I² = 0%, P = 1.0 
LDL-chol (mg/dL) 
MT 9 186 182 -13.42 [-15.94, -10.91] † < 0.00001* χ² = 98.19, I² = 92%, P < 0.00001 
LT 3 90 97 -0.22 [-13.57, 13.13] † 0.97 χ² = 0.86, I² = 0%, P = 0.65 
Triglycerides 
(mg/dL) 
MT 14 225 220 -5.75 [-9.62, -1.87] † 0.004* χ² = 28.15, I² = 54%, P = 0.009 
LT 3 90 97 -17.69 [-36.83, 1.45] † 0.07 χ² = 3.89, I² = 49%, P = 0.14 
Fasted insulin 
(µU/ml) 
MT 11 139 128 -1.44 [-2.43, -0.45] † 0.004* χ² = 38.07, I² = 74%, P < 0.0001 
HOMA-IR MT 4 43 40 -2.84 [-3.19, -2.50] † < 0.00001* χ² = 3.31, I² = 9%, P = 0.35 
Fasted glucose 
(mg/dL) 
MT 14 187 180 -2.19 [-4.09, -0.29] † 0.02* χ² = 59.26, I² = 78%, P < 0.00001 
LT 2 26 34 -25.57 [-40.04, -11.10] † 0.0005* χ² = 1.02, I² = 2%, P = 0.0005 
CRP (mg/L) MT 4 58 58 -2.47 [-3.97, -0.98] † 0.001* χ² = 9.93, I² = 70%, P = 0.02 
 
Table 9.  GRADE summary of findings.  
Outcome 
Anticipated absolute effects (95% CI) Number of 
participants 
(RCTs) 
Certainty 
Risk with no exercise 
control or usual care 
Risk with resistance 
exercise training 
Cardiovascular 
morbidity and 
mortality 
Could not be calculated due to lack of reporting. 
SBP (mmHg) ST The mean SBP – ST was 
115.45 mmHg 
MD 3.17 mmHg lower  
(6.95 lower to 0.6 higher) 
116 
(4 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
MT The mean SBP – MT was 
122.8 mmHg 
MD 4.02 mmHg lower  
(5.92 lower to 2.11 lower) 
1456 
(46 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean SBP – LT was 
131.6 mmHg 
MD 4.88 mmHg lower  
(10.55 lower to 0.78 
higher) 
346 
(7 RCTs) 
⊕⊕◯◯ 
LOW a,c 
MAP (mmHg) ST The mean MAP- ST was 
86.5 mmHg 
MD 3.31 mmHg lower  
(6.86 lower to 0.78 higher) 
67 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
MT The mean MAP- MT was 
79.6 mmHg 
MD 1.57 mmHg lower  
(4.6 lower to 1.46 higher) 
238 
(10 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
DBP (mmHg) ST The mean DBP – ST was 
65.2 mmHg 
MD 1.44 mmHg lower  
(4.73 lower to 1.86 higher) 
52 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
MT The mean DBP – MT was 
74.3 mmHg 
MD 1.73 mmHg lower  
(2.88 lower to 0.57 lower) 
1418 
(45 RCTs) 
⊕⊕◯◯ 
LOW a,c 
LT The mean DBP - LT was 
76.0 mmHg 
MD 4.93 mmHg lower  
(8.58 lower to 1.28 lower) 
346 
(7 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
RHR (bpm) ST The mean RHR– ST was 
72 bpm 
MD 2.66 bpm lower  
(7.55 lower to 2.23 higher) 
30 
(2 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
MT The mean RHR– MT was 
67.8 bpm  
MD 0.35 bpm higher  
(1.44 lower to 2.13 higher) 
977 
(35 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean RHR – LT was 
57.4 bpm 
MD 0.48 bpm lower  
(3.12 lower to 2.17 higher) 
142 
(5 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,e 
Flow Mediated 
Dilatation (%) 
The mean Flow Mediated 
Dilatation was 7.8 % 
MD 1.69 % higher  
(0.97 higher to 2.41 higher) 
138 
(6 RCTs) 
⊕⊕◯◯ 
LOW a,c 
Total 
Cholesterol 
(mg/dL)  
 
ST The mean Total 
Cholesterol – ST was 
179.3 mg/dL 
MD 5.55 mg/dL lower  
(9.62 lower to 5.47 higher) 
146 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,e 
MT The mean Total 
Cholesterol – MT was 
180.9 mg/dL 
MD 0.57 mg/dL higher  
(5.63 lower to 6.77 higher) 
882 
(32 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean Total 
Cholesterol – LT was 
198.6 mg/dL 
MD 8.71 mg/dL lower  
(30.83 lower to 13.4 
higher) 
212 
(8 RCTs) 
⊕◯◯◯ 
VERY LOW 
a,b,c,d,e 
HDL-chol 
(mg/dL)  
 
ST The mean HDL-Chol – ST 
was 53.8 mg/dL 
MD 0.82 mg/dL higher  
(5.4 lower to 7.03 higher) 
146 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,e 
MT The mean HDL-Chol – MT 
was 53.3 mg/dL 
MD 2.35 mg/dL higher  
(0.66 lower to 5.35 higher) 
1114 
(38 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean HDL-Chol – LT 
was 53.5 mg/dL 
MD 2.79 mg/dL higher  
(0.69 lower to 6.82 higher) 
339 
(9 RCTs) 
⊕⊕◯◯ 
LOW a,c 
LDL-chol 
(mg/dL)  
 
ST The mean LDL-Chol – ST 
was 105.6 mg/dL 
MD 5.1 mg/dL lower  
(11.09 lower to 0.9 higher) 
146 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,e 
MT The mean LDL-Chol - MT 
was 110.1 mg/dL 
MD 2.86 mg/dL lower  
(8.77 lower to 3.05 higher) 
1000 
(31 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean LDL-Chol - LT 
was 118.3 mg/dL 
MD 3.69 mg/dL lower 
(10.99 lower to 3.6 higher) 
265 
(6 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
Triglycerides 
(mg/dL)  
 
ST The mean Triglycerides -
ST was 115.2 mg/dL 
MD 3.63 mg/dL lower 
(17.45 lower to 10.2 
higher) 
146 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,e 
MT The mean Triglycerides - 
MT was 91.8 mg/dL 
MD 3.99 mg/dL lower 
(8.78 lower to 0.8 higher) 
1165 
(37 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean Triglycerides -
LT was 102.7 mg/dL 
MD 2.82 mg/dL lower  
(14.98 lower to 9.33 
higher) 
265 
(6 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
 Fasted 
insulin 
(μU/ml)  
 
MT The mean Insulin (fasted) 
– MT was 16.2 μU/ml 
MD 1.11 μU/ml lower  
(1.74 lower to 0.49 lower) 
590 
(20 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean Insulin (fasted) 
- LT was 13.8 μU/ml 
MD 0.4 μU/ml lower  
(1.62 lower to 0.81 higher) 
179 
(4 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
HOMA-IR  
 
MT The mean Insulin 
Resistance (HOMA) – MT 
was 6.1 
MD 1.22 lower 
(2.29 lower to 0.15 lower) 
184 
(9 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
LT The mean Insulin 
Resistance (HOMA) – LT 
was 3.8 
MD 0.18 lower  
(0.64 lower to 0.27 higher) 
71 
(3 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
Fasted 
glucose 
(mg/dL)  
 
ST The mean Glucose – ST 
was 87.3 mg/dL 
MD 3.39 mg/dL lower  
(6.9 lower to 0.11 higher) 
122 
(2 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
MT The mean Glucose – MT 
was 100.7 mg/dL 
MD 2.39 mg/dL lower  
(4.47 lower to 0.31 lower) 
984 
(34 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
LT The mean Glucose – LT 
was 92.3 mg/dL 
MD 0.7 mg/dL lower  
(2.8 lower to 2.67 higher) 
271 
(7 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,d 
CRP (mg/L)  
 
ST The mean hs-CRP – ST 
was 2.4 mg/L 
MD 0.13 mg/L lower  
(0.25 lower to 0.01 lower) 
82 
(2 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c,e 
MT The mean hs-CRP – MT 
was 3.2 mg/L 
MD 0.11 mg/L lower  
(0.6 lower to 0.38 higher) 
394 
(12 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d 
V̇O2max 
(ml/kg/min) 
ST The mean  V̇O2max – ST 
was 28.6 ml/kg/min 
MD 2.07 ml/kg/min higher  
(0.75 higher to 3.39 higher) 
308 
(9 RCTs) 
⊕◯◯◯ 
VERY LOW a,b,c 
MT The mean  V̇O2max  - MT 
was 28.9 ml/kg/min 
MD 1.07 ml/kg/min higher  
(0.38 higher to 1.76 higher) 
1454 
(48 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,d,e 
LT The mean  V̇O2max  - LT 
was 23 ml/kg/min 
MD 1.22 ml/kg/min higher  
(0.44 higher to 2.0 higher) 
399 
(11 RCTs) 
⊕◯◯◯ 
VERY LOW a,c,e 
CI - Confidence interval; RCTs – randomised control trials; MD – mean difference; ST – short term; MT – 
medium term; LT – long term; SBP – systolic blood pressure; DBP - diastolic blood pressure; MAP – 
mean arterial pressure; RHR – resting heart rate; HDL-chol – high density lipoprotein cholesterol; LDL-
chol – low density lipoprotein cholesterol; HOMA-IR – insulin resistance; CRP – C-reactive protein; 
V̇O2max – aerobic capacity. 
a – Downgraded due to being a surrogate outcome. 
b – Downgraded due to potential for a recommendation or clinical course of action differing if the upper 
versus the lower boundary of the CI represented the truth and/or a sample size <400. 
c – Publication bias suspected after inspection of funnel plots. 
d – Inconsistent due to high heterogeneity, non-overlap of CI and/or markedly dissimilar point estimates. 
e – Risk of bias was judged to be high. 
Table 8.  Sensitivity analysis of the short- (ST), medium- (MT) and long-term (LT) effects of RET on cardiometabolic outcomes. 
 
Outcome 
Number of 
studies 
Number of participants Mean difference 
[95% CI] 
P values Heterogeneity 
RT CON 
SBP (mmHg) ST 2 22 20 -2.49 [-7.14, 2.16] 0.29 χ² = 0.32, I² = 0%, P = 0.27 * 
MT 39 607 572 -4.14 [-6.36, -1.92] 0.0003 χ² = 301.18, I² = 87%, P < 0.00001 
LT 5 151 135 -3.88 [-11.18, 3.42] 0.3 χ² = 17.62, I² = 77%, P = 0.001 
DBP (mmHg) ST 2 22 20 0.41 [-2.36, 3.18] 0.77 χ² = 0.04, I² = 0%, P = 0.84 * 
MT 38 597 564 -1.86 [-3.19, -0.52] 0.006 χ² = 231.14, I² = 84%, P < 0.00001 
LT 5 138 138 -3.99 [-6.34, -1.64] 0.0009 χ² = 5.29, I² = 24%, P = 0.26 * 
MAP (mmHg) ST 2 22 20 -1.38 [-4.30, 1.54] 0.35 χ² = 0.04, I² = 0%, P = 0.85 * 
MT 9 128 125 -1.22 [-4.34, 1.90] 0.44 χ² = 95.95, I² = 92%, P < 0.00001 
Resting Heart Rate (bpm) † § MT 30 450 414 0.91 [-0.99, 2.81] 0.35 χ² = 236.88, I² = 88%, P < 0.00001 
FMD (%)  6 68 70 1.69 [0.97, 2.41] < 0.0001 χ² = 0.72, I² = 0%, P = 0.98 
V̇O2max (ml/kg/min) ST 7 159 115 1.52 [-0.13, 3.17] 0.07 χ² = 10.10, I² = 41%, P = 0.12 
MT 36 631 568 1.25 [0.45, 2.05] 0.002 χ² = 119.6, I² = 71%, P < 0.00001 
LT 6 128 101 1.82 [0.60, 3.04] 0.003 χ² = 0.6, I² = 0%, P = 0.99 * 
Total Cholesterol (mg/dL) ST 2 70 56 -2.07 [-9.62, 5.47] 0.59 χ² = 0.01, I² = 0%, P = 0.92 * 
MT 26 336 325 -3.78 [-9.12, 1.57] 0.17 χ² = 66.33, I² = 62%, P < 0.0001 * 
LT 4 56 52 -6.31 [-18.30, 5.68] 0.3 χ² = 1.34, I² = 0%, P = 0.72 * 
HDL-chol (mg/dL) ST 2 70 56 -2.17 [-6.26, 1.91] 0.3 χ² = 0.03, I² = 0%, P = 0.86 * 
MT 33 495 475 2.64 [-1.03, 6.31] 0.16 χ² =563.25, I² = 94%, P < 0.00001 * 
LT 5 120 115 0.80 [-3.07, 4.66] 0.12 χ² = 3.12, I² = 0%, P = 0.54 * 
LDL-chol (mg/dL) ST 2 70 56 -4.78 [-10.98, 1.42] 0.13 χ² = 0.17, I² = 0%, P = 0.68 
MT 25 397 382 -7.17 [-13.24, -1.09] 0.02 χ² = 147.44, I² = 84%, P < 0.00001 * 
LT 4 109 96 -3.97 [-11.86, 3.92] 0.32 χ² = 1.57, I² = 0%, P = 0.67 
Triglycerides (mg/dL) ST 2 70 56 -4.36 [-19.10, 10.37] 0.56 χ² = 0.06, I² = 0%, P = 0.81 
MT 32 492 471 -5.06 [-10.64, 0.53] 0.08 χ² = 233.71, I² = 87%, P < 0.00001 
LT 4 109 96 0.19 [-7.78, 8.16] 0.96 χ² = 1.93, I² = 0%, P = 0.59 * 
Fasted insulin (µU/ml) MT 16 246 226 -1.52 [-2.66, -0.39] 0.009 χ² = 47.11, I² = 66%, P < 0.0001 * 
LT 4 89 90 -0.60 [-1.93, 0.72] 0.37 χ² = 45.43, I² = 93%, P < 0.00001 
HOMA-IR MT 9 86 78 -1.40 [-2.58, -0.22] 0.02 χ² = 74.57, I² = 91%, P < 0.00001 * 
LT 3 38 33 -0.18 [-0.64, 0.27] 0.6 χ² = 1.45, I² = 0%, P = 0.48 
Fasted glucose (mg/dL) ST 2 64 58 -3.39 [-6.90, 0.11] 0.06 χ² = 1.66, I² = 40%, P = 0.2 
MT 27 410 397 -2.91 [-5.34, -0.47] 0.02 χ² = 310.64, I² = 91%, P < 0.00001 
LT 5 109 102 0.96 [-1.45, 3.38] 0.43 χ² = 31.42, I² = 87%, P < 0.00001 
CRP (mg/L) † MT 9 135 135 0.04 [-0.30, 0.38] 0.8 χ² = 7.59, I² = 0%, P = 0.47 * 
† ST could not be calculated due to a lack of studies. 
§ LT could not be calculated due to a lack of studies.  
* Reduction in heterogeneity 
Fig 1. Funnel plot of studies reporting systolic blood pressure.
Fig 2. Funnel plot of studies reporting diastolic blood pressure.
Fig 3. Funnel plot of studies reporting mean arterial pressure.
Fig 4. Funnel plot of studies reporting resting heart rate.
Fig 5. Funnel plot of studies reporting V̇O2max.
Fig 6. Funnel plot of studies reporting total cholesterol levels.
Fig 7. Funnel plot of studies reporting high density lipoprotein cholesterol levels.
Fig 8. Funnel plot of studies reporting low density lipoprotein cholesterol levels.
Fig 9. Funnel plot of studies reporting triglyceride levels.
Fig 10. Funnel plot of studies reporting fasted insulin levels.
Fig 11. Funnel plot of studies reporting insulin resistance (HOMA-IR).
Fig 12. Funnel plot of studies reporting fasted glucose levels.
Fig 13. Funnel plot of studies reporting c-reactive protein levels.
Fig 14. Short-, medium-, long-term effects of resistance exercise training on systolic blood pressure 
as standardised mean difference and 95% CI.
Fig 15. Short-, medium-, long-term effects of resistance exercise training on diastolic blood pressure 
as standardised mean difference and 95% CI.
Fig 16. Short- and medium-term effects of resistance exercise training on mean arterial pressure 
as standardised mean difference and 95% CI.
Fig 17. Short-, medium-, long-term effects of resistance exercise training on resting heart rate 
as standardised mean difference and 95% CI.
Fig 18. Short-, medium-, long-term effects of resistance exercise training on V̇O2max as 
standardised mean difference and 95% CI.
Fig 19. The effects of resistance exercise training on flow mediated dilatation as standardised 
mean difference and 95% CI.
Fig 20. Short-, medium-, long-term effects of resistance exercise training on total cholesterol levels 
as standardised mean difference and 95% CI.
Fig 21. Short-, medium-, long-term effects of resistance exercise training on high density 
lipoprotein cholesterol levels as standardised mean difference and 95% CI.
Fig 22. Short-, medium-, long-term effects of resistance exercise training on low density 
lipoprotein cholesterol levels as standardised mean difference and 95% CI.
Fig 23. Short-, medium-, long-term effects of resistance exercise training on triglyceride levels 
as standardised mean difference and 95% CI.
Fig 24. Medium- and long-term effects of resistance exercise training on fasted insulin levels 
as standardised mean difference and 95% CI.
Fig 25. Medium- and long-term effects of resistance exercise training on insulin resistance (HOMA-
IR) as standardised mean difference and 95% CI.
Fig 26. Short-, medium-, long-term effects of resistance exercise training on fasted glucose levels 
as standardised mean difference and 95% CI.
Fig 27. Short- and medium-term effects of resistance exercise training on c-reactive protein levels 
as standardised mean difference and 95% CI.
